

1 **Ankyrin-R regulates fast-spiking interneuron excitability through perineuronal nets and**
2 **Kv3.1b K⁺ channels**

3

4 Sharon R. Stevens¹, Colleen M. Longley^{2,3}, Yuki Ogawa¹, Lindsay H. Teliska¹,
5 Anithachristy S. Arumanayagam⁴, Supna Nair⁵, Juan A. Oses-Prieto⁵, Alma L. Burlingame⁵,
6 Matthew D. Cykowski⁴, Mingshan Xue^{1,2,3,6}, and Matthew N. Rasband^{1,2}

7

8 ¹Department of Neuroscience, ²Program in Developmental Biology, ⁶Department of Molecular
9 and Human Genetics, Baylor College of Medicine, Houston, TX, USA.

10 ³The Cain Foundation Laboratories, Jan and Dan Duncan Neurological Research Institute at
11 Texas Children's Hospital, Houston, TX, USA.

12 ⁴Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX,
13 USA.

14 ⁵Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco,
15 CA, USA.

16

17

18 **Address correspondence to:**

19 Matthew N. Rasband, PhD
20 Department of Neuroscience
21 Baylor College of Medicine
22 One Baylor Plaza
23 Houston, Texas 77030
24 Tel: 713-798-4494
25 Fax: 713-798-3946
26 E-mail: rasband@bcm.edu

27

28 Running title: AnkR in the nervous system

29

30 Word count: Abstract, 146; Introduction, results, and discussion combined, 5431.

31 Figures, 7. Supplemental Figures, 6. Supplemental Table, 1. Supplemental Movies, 2.

32

33 Key words: Perineuronal net, cytoskeleton, scaffolding protein, inhibitory neurons, K⁺ channels

34

35

36 **ABSTRACT**

37 Neuronal ankyrins cluster and link membrane proteins to the actin and spectrin-based
38 cytoskeleton. Among the three vertebrate ankyrins, little is known about neuronal Ankyrin-R
39 (AnkR). We report AnkR is highly enriched in Pv⁺ fast-spiking interneurons in mouse and
40 human. We identify AnkR-associated protein complexes including cytoskeletal proteins, cell
41 adhesion molecules (CAMs), and perineuronal nets (PNNs). We show that loss of AnkR from
42 forebrain interneurons reduces and disrupts PNNs, decreases anxiety-like behaviors, and
43 changes the intrinsic excitability and firing properties of Pv⁺ fast-spiking interneurons. These
44 changes are accompanied by a dramatic reduction in Kv3.1b K⁺ channels. We identify a novel
45 AnkR-binding motif in Kv3.1b, and show that AnkR is both necessary and sufficient for Kv3.1b
46 membrane localization in interneurons and at nodes of Ranvier. Thus, AnkR regulates Pv⁺ fast-
47 spiking interneuron function by organizing ion channels, CAMs, and PNNs, and linking these to
48 the underlying β 1 spectrin-based cytoskeleton.

49 INTRODUCTION

50 Ion channels and cell adhesion molecules (CAMs) are frequently recruited to, stabilized,
51 and maintained at specific neuronal membrane domains by scaffolding proteins. The ankyrin
52 scaffolding proteins, consisting of Ankyrin-R, -B, and -G (AnkR, AnkB, and AnkG, respectively),
53 are the primary link between the submembranous spectrin-based cytoskeleton and the
54 cytoplasmic domains of many transmembrane proteins (Michaelis and Bennett, 1995; Sedgwick
55 and Smerdon, 1999). For example, AnkG links Na⁺ and K⁺ channels, and the CAM neurofascin
56 186 (NF186) at axon initial segments (AIS) and nodes of Ranvier to the underlying β 4 spectrin
57 and actin-based cytoskeleton. The clustering of channels at the AIS and nodes facilitates fast
58 and efficient action potential propagation (Dzhashvili et al., 2007; Zhou et al., 1998).
59 Similarly, AnkB stabilizes Na⁺ channels and L1CAM family membrane proteins in unmyelinated
60 axons and at paranodal junctions of myelinated axons by linking these membrane proteins to
61 β 2 spectrin (Chang et al., 2014; Scotland et al., 1998; Susuki et al., 2018). However, little is
62 known about the function of AnkR in the nervous system. Instead, AnkR has mostly been
63 studied in red blood cells where it maintains the cell's structural integrity via its link between β 1
64 spectrin and the cytoplasmic domain of the anion exchanger Band 3 (Bennett and Stenbuck,
65 1979). Loss of AnkR results in fragile erythrocyte membranes and hemolytic anemia (Lux et al.,
66 1990). Intriguingly, case studies of patients with hereditary spherocytic anemia, caused by
67 mutations in AnkR, report various neurological disturbances (Coetzer et al., 1988; McCann and
68 Jacob, 1976; Miya et al., 2012), and a number of recent epigenome-wide association studies in
69 Alzheimer's disease (AD) have consistently found neuropathology-associated DNA
70 hypermethylation of *ANK1* (*ANK1* is the gene encoding AnkR) (De Jager et al., 2014; Gasparoni
71 et al., 2018; Higham et al., 2019; Lunnon et al., 2014; Smith et al., 2019a; Smith et al., 2019b).
72 Additionally, AnkR can substitute for AnkG to cluster Na⁺ channels at nodes of Ranvier (Ho et al.,
73 2014) but not AIS (Liu et al., 2020a). Thus, AnkR may play important, but as yet undefined,
74 roles in nervous system function in both the healthy and diseased brain.

75 In addition to clustering ion channels, and through its interaction with CAMs, AnkG
76 assembles and maintains a complex extracellular matrix (ECM) consisting of chondroitin sulfate
77 proteoglycans (CSPGs) and other ECM proteins that surround AIS and nodes of Ranvier (Amor

78 et al., 2017; Hedstrom et al., 2007; Susuki et al., 2013). Thus, ankyrins may function generally to
79 link ECMs to the cytoskeleton through their membrane receptors. One highly condensed and
80 specialized ECM in the nervous system is the perineuronal net (PNN). PNNs surround synaptic
81 innervations and are thought to be important to maintain the balance of excitation and
82 inhibition (Carceller et al., 2020). The majority of PNNs surround the soma and proximal
83 dendrites of fast-spiking parvalbumin-positive (Pv⁺) inhibitory interneurons and have a CSPG
84 composition similar to the perinodal and AIS ECM (Fawcett et al., 2019). However, how PNNs
85 themselves are assembled, maintained, and restricted to specific domains and neuronal
86 subtypes, is unknown.

87 Here, we show the loss of AnkR from GABAergic forebrain neurons results in a reduction
88 and altered structure of PNNs, a reduction in anxiety-like behaviors, and altered intrinsic
89 excitability and firing properties of PNN⁺ fast-spiking interneurons. We identify AnkR-
90 interacting adhesion molecules that may tether PNNs to the spectrin cytoskeleton. Importantly,
91 the altered excitability reflects the loss of Kv3.1b K⁺ channels. We identify the motif in Kv3.1b
92 necessary for its interaction with AnkR. We show AnkR is both necessary and sufficient for the
93 recruitment and clustering of Kv3.1b K⁺ channels in the neuronal membrane.

94

95 **RESULTS**

96 **AnkR is highly enriched in Pv⁺ inhibitory interneurons**

97 To determine where AnkR is located, we immunostained mouse forebrain using
98 antibodies against AnkR. We found that AnkR is highly enriched in the soma and proximal
99 dendrites of a subset of neurons sparsely distributed throughout the cortex and hippocampus
100 (**Fig. 1A**). Immunoblotting of brain homogenates shows AnkR protein in the brain increases
101 during early postnatal development, peaking by postnatal day 30 (**Fig. 1B**). The sparse
102 distribution of AnkR-labeled cells was highly reminiscent of the distribution of cortical
103 interneurons. Indeed, immunostaining with antibodies against parvalbumin (Pv), a marker of
104 fast-spiking interneurons (**Fig. 1C, D**), shows >90% of Pv⁺ cells in postnatal day 56 (P56) cortex
105 and hippocampus have high levels of AnkR, while only ~70% of AnkR⁺ cells in cortex and
106 hippocampus are Pv⁺. AnkR is also highly expressed in Pv⁺ neurons in human brain. AnkR

107 staining was identified in laminae II-VI in human cortical biopsy samples. Labeling was strong
108 and membranous and was most intense in larger neurons of laminae III and V (**Fig. 1E**). AnkR
109 staining intensity in large neurons of lamina III and V was similar to staining intensity of
110 erythrocytes (not shown). Furthermore, AnkR labeling was only identified in a subset of
111 neurons in human cortex and staining was not present in endothelial cells or glia. A subset of
112 AnkR⁺ neurons in laminae III and V co-expressed Pv in the neuronal cytoplasm (**Fig. 1E**),
113 although, as in mice, the total number of AnkR⁺ positive neurons exceed the number of Pv⁺
114 cells. These results expand on those previously reported in rat neocortex (Wintergerst et al.,
115 1996).

116 To determine the role of neuronal AnkR and confirm its high expression in interneurons,
117 we constructed a floxed allele for *Ank1* (*Ank1^{F/F}*; **Fig. 1F**); this new model allows for an
118 exploration of AnkR function in the brain while avoiding the confound of anemia due to loss of
119 AnkR from red blood cells. We removed AnkR from the nervous system using *Nestin-Cre* mice
120 (*Ank1^{F/F};Nes-Cre*), and from GABAergic forebrain interneurons using *Dlx5/6-Cre* mice
121 (*Ank1^{F/F};Dlx5/6-Cre*). We confirmed the efficient loss of AnkR after recombination by
122 immunoblot of *Ank1^{F/F};Nes-Cre* brain homogenates (**Fig. 1G**). Moreover, immunostaining of
123 forebrain sections from both *Ank1^{F/F};Nes-Cre* and *Ank1^{F/F};Dlx5/6-Cre* showed efficient and
124 selective loss of AnkR in neurons; AnkR expression in erythrocytes was unaffected
125 (**Supplemental Fig. 1A**). These results also highlight the specificity of our antibodies.
126 Additionally, hemoglobin levels in *Ank1^{F/F};Nes-Cre* and *Ank1^{F/F};Dlx5/6-Cre* mice were normal
127 (data not shown). Although most Pv⁺ cells are AnkR⁺ (**Fig. 1C, D**) there is a subpopulation of
128 AnkR⁺ neurons that are not Pv⁺; these cells are most likely another subtype of GABAergic
129 neuron since neurons with high levels of AnkR immunoreactivity in cortical and hippocampal
130 neurons were not detected in *Ank1^{F/F};Dlx5/6-Cre* mice (**Supplemental Fig. 1A**). Interestingly,
131 and in contrast to the rescue of AnkG by AnkR at nodes of Ranvier (Ho et al., 2014), we found no
132 evidence for reciprocal compensation by AnkG in AnkR-deficient neurons. AnkG in Pv⁺ neurons
133 in cortex remained highly restricted to the AIS and nodes in all genotypes analyzed
134 (**Supplemental Fig. 1B** and data not shown). Together, these results show that AnkR is
135 abundantly expressed in Pv⁺ interneurons of the forebrain, that its localization is distinct from

136 that of AnkB and AnkG, and that we have generated a floxed *Ank1* allele that allows for cell-
137 type specific deletion in the nervous system.

138

139 **Elucidating the AnkR interactome**

140 What functions does AnkR have in GABAergic forebrain interneurons? To begin to
141 answer this question we determined AnkR's interactome. Since AnkR and β 1 spectrin are
142 binding partners in erythrocytes and can function together at nodes of Ranvier to stabilize Na⁺
143 channels (Liu et al., 2020b), we first showed that AnkR and β 1 spectrin also form a protein
144 complex in Pv⁺ interneurons. Immunostaining showed that β 1 spectrin is highly expressed and
145 colocalizes with AnkR in forebrain interneurons (**Fig. 2A**). Furthermore, β 1 spectrin and AnkR
146 reciprocally co-immunoprecipitate each other (**Fig. 2B**). Immunoblots of *Ank1^{F/F};Nes-Cre* mouse
147 brain homogenates show that β 1 spectrin protein levels are significantly reduced in the
148 absence of AnkR compared to control mice (**Fig. 2C**). Similarly, immunostaining of cortex and
149 hippocampus from *Ank1^{F/F};Nes-Cre* mice showed remarkably reduced β 1 spectrin
150 immunofluorescence compared to control mice (**Supplemental Fig. 2A, B**). Together, these
151 results show that AnkR interacts with and maintains β 1 spectrin in Pv⁺ forebrain interneurons.

152 To identify additional AnkR interacting proteins, we combined two unbiased mass
153 spectrometry screens (**Supplemental Fig. 2C**). First, we performed mass spectrometry on AnkR
154 immunoprecipitations (IPs) in biological triplicate from whole *Ank1^{F/F}* mouse brain lysates.
155 These yielded 3241 unique proteins with at least one peptide spectral match (PSM) in each
156 sample. We further narrowed the number of potential AnkR-binding proteins by setting an
157 arbitrary threshold of ≥ 10 mean PSMs found in the IPs. As a second, orthogonal approach, we
158 performed differential proteomics and mass spectrometry using wildtype (*Ank1^{+/+}* or WT) and
159 AnkR-deficient (*Ank1^{pale/pale}* or AnkR-KO)(Ho et al., 2014) hindbrain homogenates
160 (**Supplemental Fig. 2C**). We used AnkR-KO mice rather than *Ank1^{F/F};Nes-Cre* mice to avoid
161 confounds due to incomplete recombination or contributions from cells still expressing AnkR.
162 Mass spectrometry yielded 2465 unique proteins, of which 986 were reduced in AnkR-KO mice
163 compared to WT. Since ankyrins function as scaffolds that stabilize and retain membrane
164 proteins, we reasoned that loss of AnkR might result in increased turnover and lower amounts

165 of AnkR-interacting proteins. Therefore, we focused only on those proteins that had fewer
166 PSMs in the AnkR-KO compared to WT. To further refine our analysis, we set an arbitrary
167 threshold such that potential AnkR-interacting proteins must have $\geq 20\%$ reduction in PSMs,
168 with ≥ 5 PSMs found in WT mice and a ≥ 3 PSMs difference between WT and AnkR-KO.
169 Combining the two data sets revealed 72 potential AnkR-interacting proteins (**Supplemental**
170 **Fig. 2C**).

171 We sorted these 72 proteins into functional categories and plotted them using
172 concentric rings to indicate the percent reduction in AnkR-KO mice, with circle size representing
173 the mean number of PSMs in the IPs (**Fig. 2D**). Among the proteins enriched and passing our
174 stringent filtering criteria, we found cytoskeletal, membrane, signaling, and ECM proteins.
175 Surprisingly, although AnkR is a cytoplasmic scaffolding protein, the ECM proteins TenascinC
176 (TnC), TenascinR (TnR), Brevican (Bcan) and Versican (Vcan) were all identified in the AnkR IPs
177 and also enriched in WT compared to AnkR-KO. We previously reported that AnkG, through the
178 CAM NF186, interacts with and recruits the CSPGs Bcan and Vcan to AIS and nodes of Ranvier
179 (Hedstrom et al., 2008; Susuki et al., 2013). TnR is also found at nodes and binds to Vcan and
180 Bcan (Bekku et al., 2009). Immunostaining of cortex revealed that antibodies against TnR and
181 Bcan strongly label AnkR⁺ neurons (**Figs. 2E, F**); Vcan immunoreactivity was not restricted to
182 AnkR⁺ neurons and was more widely distributed (**Fig. 2H**). TnR, Bcan and Vcan are well known
183 components of PNNs (Fawcett et al., 2019; Wintergerst et al., 1996). Immunostaining for the
184 CSPG and PNN protein Aggrecan (Acan) (Carulli et al., 2007; Rowlands et al., 2018) also showed
185 strong colocalization with AnkR (**Fig. 2G**); although Acan was detected by mass spectrometry, it
186 did not pass our stringent filtering. In addition to antibodies against Bcan, TnR, and Acan, PNNs
187 can also be detected using the fluorescently-labeled *Wisteria Floribunda* (WFA) lectin (Bruckner
188 et al., 1993), which binds to *N*-acetyl-D-glucosamine at the ends of chondroitin sulfate chains.
189 Co-staining of WFA and AnkR shows that AnkR⁺ neurons are surrounded by WFA-labeled PNNs
190 (**Fig. 2I**).

191 How can AnkR, an intracellular scaffolding protein, interact with extracellular PNNs? We
192 reasoned this could occur through CAMs that bridge AnkR and PNNs. Our list of potential AnkR-
193 binding CAMs included two strong candidates: NrCAM and PlexinA4. NrCAM is a member of

194 the L1 family of CAMs with known ankyrin-binding activity (Davis and Bennett, 1994). However,
195 NrCAM can also be shed from the cell surface and incorporated into the ECM surrounding
196 nodes of Ranvier through direct binding to NF186 (Susuki et al., 2013). Thus, NrCAM can
197 function both as a membrane receptor and as a component of the perinodal ECM.
198 Immunostaining for NrCAM showed strong colocalization with both AnkR⁺ and WFA⁺ neurons in
199 caudoputamen (**Fig. 2J** and **Supplemental Fig. 2G**), but less robust colocalization in
200 hippocampus and cortex (**Supplemental Figs. 2D-F**). These results suggest AnkR may function
201 together with NrCAM in a subset of GABAergic neurons and emphasizes the diversity of PNNs
202 and their interacting proteins. Somatodendritic, but not AIS, NrCAM immunoreactivity was
203 dramatically reduced in *Ank1^{F/F};Nes-Cre* mouse brain (**Fig. 2J**). Furthermore, NrCAM and AnkR
204 reciprocally co-immunoprecipitate each other, while the axonal membrane protein Caspr,
205 normally found at paranodal junctions of myelinated axons, does not (**Fig. 2K**). These results
206 support recent work exploring the molecular heterogeneity of PNNs and suggests another
207 potential PNN subtype involving a unique CAM membrane receptor (Irvine and Kwok, 2018;
208 Yamada and Jinno, 2017).

209 PlexinA4 functions together with Neuropilin-1 (Nrp1) as a receptor for semaphorin
210 signaling (Nakamura et al., 2000). Sema3A is a component of the PNNs surrounding Pv⁺
211 interneurons (Kwok et al., 2011); moreover, enzymatic or genetic disruption of PNNs reduces
212 Sema3A (de Winter et al., 2016). PlexinA4 and Nrp1 are widely expressed throughout the
213 nervous system. Although immunostaining did not reveal any specific enrichment for PlexinA4
214 in AnkR⁺ interneurons, immunostaining for Nrp1 showed strong enrichment in AnkR⁺ neurons in
215 deep cerebellar nuclei (**Supplemental Fig. 2I**). Nevertheless, we found that PlexinA4 and Nrp1
216 co-immunoprecipitated with AnkR from brain homogenates (**Fig. 2L**). Together, our proteomic
217 studies show that AnkR co-localizes with multiple PNN proteins and may indirectly interact with
218 PNNs through the membrane receptors NrCAM and PlexinA4. Other membrane proteins
219 identified in our proteomics, but not analyzed here, may also function to link PNNs to AnkR.
220 Based on these proteomic, biochemical, and immunostaining results, we focused on the
221 relationship between AnkR and PNNs.

222

223 **AnkR is required to maintain PNN density and structure**

224 To determine if AnkR contributes to the formation, maintenance, and structure of PNNs,
225 we used WFA to label PNNs in cortex and hippocampus of one-month-old *Ank1^{F/F}*,
226 *Ank1^{+/+};Dlx5/6-Cre*, and *Ank1^{F/F};Dlx5/6-Cre* mice (**Fig. 3A**). At this age, we found little difference
227 in the number of WFA⁺/Pv⁺, WFA⁻/Pv⁺, or WFA⁺/Pv⁻ neurons per unit area (UA) in either
228 hippocampus or cortex (**Fig. 3B**). However, when we measured the fluorescence intensity of
229 WFA, we found a significant reduction in both cortex and hippocampus in *Ank1^{F/F};Dlx5/6-Cre*
230 mice compared to floxed or Cre controls (**Fig. 3C**); further subdividing cortical regions showed a
231 similar decrease (**Supplemental Figs. 3A, C**). Examination of PNNs at high magnification
232 showed that in the absence of AnkR, PNNs were less compact compared to control mice. We
233 classified the PNNs as being dense (0), having a few small holes (1), or having large numerous
234 holes (2) (**Supplemental Fig. 3D**). AnkR-deficient neurons were significantly less likely to be
235 compact and more likely to have holes in their nets (**Figs. 3D, E**). In 12-month-old mice we
236 found a significant reduction in the number of WFA⁺/Pv⁺ cells per unit area in the hippocampus
237 and cortex of *Ank1^{F/F};Dlx5/6-Cre* mice compared to floxed or Cre controls (**Figs. 3F, G**). In
238 addition, and like in the one-month-old *Ank1^{F/F};Dlx5/6-Cre* mice, we measured a ~50% decrease
239 in the WFA fluorescence intensity in both hippocampus and cortex (**Fig. 3H**). This significant
240 reduction in WFA was seen in all cortical regions (**Supplemental Fig. 3B**). The normally compact
241 PNN structure, as observed in 12-month-old control mice, was also significantly disrupted in
242 *Ank1^{F/F};Dlx5/6-Cre* mice with even more prominent holes in the PNNs compared to either
243 control or one-month-old *Ank1^{F/F};Dlx5/6-Cre* mice (**Figs. 3I, J, and Supplemental Movies 1, 2**).
244 Furthermore, the strong reduction in NrCAM immunoreactivity seen in *Ank1^{F/F};Nes-Cre* mouse
245 brain (**Fig. 2J**) was matched by a strong reduction in WFA⁺ cells in the same region
246 (**Supplemental Figs. 2G, H**). Together, these results suggest that loss of AnkR does not disrupt
247 the ability of PNNs to form, but rather AnkR helps maintain PNNs and their normal compact
248 structure through binding to PNN-interacting CAMs like NrCAM and PlexinA4.

249

250 **Loss of AnkR from GABAergic forebrain interneurons decreases anxiety-like behaviors**

251 To determine if loss of AnkR from GABAergic interneurons alters nervous system
252 function, we analyzed the behavior of *Ank1^{F/F};Dlx5/6-Cre* mice compared to control mice
253 (*Ank1^{F/F}* and *Ank1^{+/+};Dlx5/6-Cre*). We first performed a 30-minute open field assessment to rule
254 out locomotor deficits (**Fig. 4A** and **Supplemental Fig. 4A-C**) since a hypomorph of AnkR was
255 previously reported to have a loss of Purkinje neurons by 6 months of age (Peters et al., 1991).
256 We found that all genotypes analyzed had normal locomotion, but both *Ank1^{+/+};Dlx5/6-Cre* and
257 *Ank1^{F/F};Dlx5/6-Cre* mice showed increased velocity and distance traveled compared to *Ank1^{F/F}*
258 mice. These results are consistent with previous reports that the *Dlx5/6-Cre* transgene results in
259 a hyperactive phenotype characterized by increased velocity and movement (de Lombares et
260 al., 2019). Nevertheless, during the open field assessment, *Ank1^{F/F};Dlx5/6-Cre* mice spent
261 significantly more time in the center of the arena and less time in the perimeter compared to
262 both *Ank1^{F/F}* and *Ank1^{+/+};Dlx5/6-Cre* mice (**Fig. 4B, C**), suggesting that loss of AnkR may be
263 anxiolytic.

264 To further distinguish between increased activity and decreased anxiety-like behaviors,
265 we used the elevated plus maze (EPM) (**Fig. 4D**). In contrast to the open field assessment,
266 during a 10-minute trial in the EPM we observed no difference among the three genotypes in
267 the velocity or total distance traveled in all arms (**Supplemental Fig. 4D-E**). However, we
268 measured a significant increase in the distance traveled in the open arms, the time spent in the
269 open arms, and the number of open arm entries performed by *Ank1^{F/F};Dlx5/6-Cre* mice
270 compared to control mice (**Fig. 4E-G**). Together, these data suggest that loss of AnkR from
271 forebrain GABAergic neurons reduces anxiety-like behaviors.

272

273 **AnkR influences the intrinsic excitability and firing properties of WFA⁺ fast-spiking** 274 **interneurons without altering their synaptic inputs**

275 To determine how loss of AnkR impacts the intrinsic excitability and firing properties of
276 fast-spiking interneurons, we performed whole-cell current clamp recordings on layer 5 PNN⁺
277 interneurons in somatosensory cortical slices from *Ank1^{F/F}*, *Ank1^{+/+};Dlx5/6-Cre*, and
278 *Ank1^{F/F};Dlx5/6-Cre* mice. Fast-spiking interneurons were identified in live brain slices by labeling
279 PNNs with fluorescent WFA (**Supplemental Fig. 5A-C**). Indeed, 64 out of 66 WFA⁺ cells recorded

280 were fast-spiking interneurons and the 2 non-fast spiking cells were not included in the analysis.
281 We found that the resting membrane potential, input resistance, membrane capacitance, and
282 rheobase current were not significantly altered in *Ank1^{F/F};Dlx5/6-Cre* neurons compared to
283 controls (**Supplemental Table 1**). We determined the action potential latency, threshold,
284 amplitude, half-width, afterhyperpolarization (AHP) amplitude, and AHP time from the single
285 action potential elicited by the rheobase current (**Figure 5A**). Loss of AnkR decreased the action
286 potential latency and threshold (**Fig. 5B, C, and Supplemental Table 1**) without changing the
287 amplitude of the action potential (**Fig. 5D, and Table 1**). Interestingly, loss of AnkR also altered
288 the shape of the action potential, resulting in a 47% broader action potential with a shallower
289 and delayed AHP (**Fig. 5E-H, and Supplemental Table 1**).

290 We also recorded trains of action potentials evoked by different levels of current
291 injection (**Fig. 5I, J**). At 2 times the action potential threshold current, fast-spiking interneurons
292 from *Ank1^{F/F};Dlx5/6-Cre* mice display a decreased firing frequency during the first 100 ms of
293 current injection (**Fig. 5K**), but normal spike frequency adaptation (**Fig. 5L**). However, the spike
294 amplitude adaptation was enhanced, resulting in a strong reduction in the amplitudes of action
295 potentials towards the end of spike trains (**Fig. 5I, M**). In fact, *Ank1^{F/F};Dlx5/6-Cre* cells often
296 entered depolarization block at much lower current levels than control cells (**Fig. 5I, N**). Thus,
297 the reduction in firing frequency for *Ank1^{F/F};Dlx5/6-Cre* cells at high levels of current injection is
298 actually an underestimation, because many *Ank1^{F/F};Dlx5/6-Cre* cells prematurely reached
299 depolarization block and were not represented by the current-firing frequency curve (**Fig. 5J**).

300 In addition to examining intrinsic excitability of fast-spiking interneurons we also
301 performed whole-cell voltage clamp recordings to record miniature postsynaptic currents. We
302 observed no significant differences between the controls and *Ank1^{F/F};Dlx5/6-Cre* mice for the
303 frequency and amplitude of miniature excitatory postsynaptic currents (mEPSC) or miniature
304 inhibitory postsynaptic currents (mIPSC), as well as the ratio of excitatory to inhibitory inputs
305 (E/I ratio) (**Supplemental Fig. 5D-I**). Taken together, these results show that loss of AnkR alters
306 the intrinsic properties of WFA⁺ fast-spiking inhibitory interneurons. Furthermore, they are
307 consistent with what has been reported in another model where PNNs of fast-spiking
308 interneurons are disrupted due to loss of Bcan (Favuzzi et al., 2017); however loss of Bcan also

309 induced changes in mPSCs. Intriguingly, the results are very similar to those seen in mice with
310 loss of Kv3 K⁺ channel expression in fast-spiking interneurons (Lau et al., 2000). Hence, we
311 hypothesize that loss of AnkR may impact Kv3 K⁺ channel function.

312

313 **AnkR recruits and maintains Kv3.1b K⁺ channels at the neuronal membrane**

314 Among the Kv channels, Kv3.1b is highly expressed in WFA⁺ cortical interneurons (Hartig
315 et al., 1999); Kv3.1b is also found at some CNS nodes of Ranvier, but not AIS (Devaux et al.,
316 2003). Similarly, AnkR is enriched in WFA⁺ cortical interneurons (**Fig. 2I**), and can be found at
317 some nodes of Ranvier (Ho et al., 2014), but not AIS (Liu et al., 2020a). Based on these
318 similarities, we considered Kv3.1b to be a good candidate to interact with AnkR in somatic
319 membranes of WFA⁺ cortical interneurons. Immunostaining of control 1- and 12-month-old
320 somatosensory cortex showed that AnkR⁺ neurons were also Kv3.1b⁺ (**Fig. 6A**, and
321 **Supplementary Fig. 6A**), and that AnkR and Kv3.1b colocalize at the neuronal membrane (**Fig.**
322 **6B**). This same colocalization was also seen in human cortex (**Fig. 6C**). Remarkably, AnkR-
323 deficient *Ank1^{F/F};Dlx5/6-Cre* mice have a profound reduction in Kv3.1b⁺ neurons at both 1- and
324 12-months of age (**Figs. 6A, B**, and **Supplementary Fig. 6A**) and nearly complete loss of Kv3.1b
325 immunofluorescence (**Fig. 6D**). Compared to controls, *Ank1^{F/F};Dlx5/6-Cre* mice have a ~50%
326 reduction in Kv3.1b protein (**Figs. 6E, F**), which persists in 12-month-old mice (**Supplementary**
327 **Fig. 6B, C**). These results show that AnkR is required to maintain clustering of Kv3.1b in the
328 somatic membrane of GABAergic interneurons.

329 To determine if AnkR and Kv3.1b interact, we co-transfected HEK cells with AnkR-GFP
330 and Flag-tagged Kv3.1b. AnkR-GFP efficiently co-precipitates full-length Flag-Kv3.1b (**Fig. 6G**).
331 We then constructed serial C-terminal truncations of Flag-Kv3.1b. We found that AnkR-GFP
332 pulled down amino acids (aa) 1-546 of Kv3.1b (**Fig. 6G**). However, additional shortening of the
333 C-terminus blocked the interaction with AnkR. Thus, AnkR binds to the region of Kv3.1b
334 including aa 510-546 (**Fig. 6G**). To further define the motif in Kv3.1b that interacts with AnkR,
335 we generated additional C-terminal deletions of just 6 aa each, spanning aa 510-546 of Kv3.1b.
336 We found that aa 516-522 of Kv3.1b (EDCPHI) are required for AnkR binding (**Fig. 6H**). A nearly
337 identical motif is also present in Kv3.3, but not Kv3.2 (**Fig. 6I**). Kv3.3 is also highly expressed in

338 P_v⁺ neurons (Chang et al., 2007) and immunostaining of control one-month-old somatosensory
339 cortex showed that a subset of AnkR⁺ neurons also express Kv3.3 (**Supplementary Fig. 6D**).
340 Using brain homogenates, we found that Kv3.1b, but not Kv2.1, co-immunoprecipitates AnkR
341 (**Fig. 6J**). However, we were unable to detect Kv3.1b after immunoprecipitation of AnkR; this
342 may suggest that only a small fraction of the total AnkR interacts with Kv3.1b. Together, these
343 results show that AnkR binds directly to Kv3.1b.

344 Since Kv3.1b interacts with AnkR and is required for its membrane localization (**Figs. 6A,**
345 **b**), we next determined if AnkR is sufficient to recruit Kv3.1b to neuronal membrane domains.
346 Although some CNS nodes of Ranvier have clustered Kv3.1b, most PNS nodes of Ranvier
347 normally have high levels of Kv7.2/3 K⁺ channels rather than Kv3.1b (**Figs. 6K, L**) (Pan et al.,
348 2006). Kv7.2 K⁺ channel clustering requires binding to AnkG since Kv7.2 is absent from nodes in
349 the ventral roots of AnkG-deficient (*Ank3^{F/F};ChAT-Cre*) mice (**Figs 6K, L**). AnkR clusters nodal
350 Na⁺ channels (Ho et al., 2014) and NF186 in the ventral roots of *Ank3^{F/F};ChAT-Cre* mice (**Fig. 6K**).
351 Although very few nodes in ventral root normally have Kv3.1b (**Figs. 6L**), the replacement of
352 AnkG by AnkR in *Ank3^{F/F};ChAT-Cre* mice is sufficient to recruit and cluster Kv3.1b to nearly all
353 nodes (**Figs. 6K, L**); and nodes in control spinal cord that have high levels of AnkR also have
354 clustered Kv3.1b (**Supplemental Fig. 6E**). Similarly, AnkR recruits Kv3.3 K⁺ channels to nodes in
355 AnkG-deficient ventral root axons (**Supplemental Fig. 6E**). Together, these results show that
356 although AnkG and AnkR can both cluster Na⁺ channels at nodes of Ranvier, AnkG preferentially
357 clusters Kv7.2/3 K⁺ channels and links them to the cytoskeleton through $\alpha 2/\beta 4$ spectrin (Huang
358 et al., 2017b), while AnkR is both necessary and sufficient to recruit Kv3.1b/3 K⁺ channels to
359 neuronal membranes and nodes of Ranvier, and links them to the cytoskeleton through $\alpha 2/\beta 1$
360 spectrin (Ho et al., 2014; Huang et al., 2017a) (**Supplemental Fig. 6G**). Thus, the type of K⁺
361 channel found at nodes of Ranvier is dictated by ankyrins.

362

363 **DISCUSSION**

364 Ankyrins are well-known to function in neurons as scaffolds that link ion channels and
365 membrane proteins to the spectrin cytoskeleton (Bennett and Lorenzo, 2013). We previously
366 showed that in the absence of AnkG, AnkR can function at nodes of Ranvier as a secondary Na⁺

367 channel clustering mechanism (Ho et al., 2014). The rescue depends on AnkR's recruitment to
368 nodes from a pre-existing, unclustered pool. These findings motivated us to determine AnkR's
369 normal functions in the nervous system since it is unlikely that AnkR functions only as a backup
370 for nodal Na⁺ channel clustering, since pathogenic *ANK1* variants are associated with nervous
371 system dysfunction, and since altered methylation of *ANK1* is associated with AD. Our
372 experiments confirm that in general, AnkR acts as a scaffolding protein like AnkB and AnkG.
373 However, unlike AnkB and AnkG which are broadly expressed in all neurons, AnkR is highly and
374 specifically enriched in subsets of neurons, including fast-spiking GABAergic interneurons,
375 where it assembles and stabilizes unique protein complexes necessary for the proper function
376 of these cells (**Fig. 7**).

377

378 **AnkR maintains PNNs**

379 GABAergic interneurons are surrounded by PNNs, and our proteomics experiments
380 revealed that AnkR indirectly interacts with PNN components (**Fig. 7**). PNNs are proposed to
381 have many functions including regulation of synaptic plasticity, excitation and inhibition, ion
382 buffering, and even protection against neurodegeneration and neurotoxicity (Cabungcal et al.,
383 2013; Fawcett et al., 2019; Suttkus et al., 2016b). The connection between AnkR and PNNs is
384 remarkably similar to the connection between AnkG and perinodal and AIS ECMs. These latter
385 ECMs interact with AnkG through the CAM NF186, and loss of either AnkG or NF186 blocks
386 their assembly (Amor et al., 2017; Hedstrom et al., 2007; Susuki et al., 2013). In contrast, the
387 membrane receptors and mechanisms of PNN assembly and maintenance are unknown. Our
388 proteomics experiments revealed candidates and suggest that NrCAM and PlexinA4, together
389 with Nrp1, may participate in assembly or maintenance of PNNs. These CAMs co-
390 immunoprecipitate with AnkR. NrCAM and Nrp1 colocalize with a subset of AnkR⁺ neurons.
391 Furthermore, loss of AnkR dramatically reduces the number of somatodendritic NrCAM⁺/WFA⁺
392 neurons, suggesting that as for PNNs, AnkR is required to maintain somatodendritic NrCAM in
393 WFA⁺ neurons. Future studies of PNNs in NrCAM and PlexinA4-deficient mice may help to
394 determine the role of these CAMs in PNN assembly and maintenance. In addition, other
395 interesting candidates identified in our proteomics experiments may also function as receptors.

396 For example, we identified the adhesion G-protein coupled receptor Gpr158 and the CAM
397 Limbic System Associated Membrane Protein (Lsamp). It will be interesting and important to
398 determine if these membrane proteins also function with AnkR to assemble, modulate, or
399 maintain PNNs, and we speculate that multiple receptors link AnkR to PNNs.

400 We observed the disruption of the compact PNN structure and a ~50% reduction in WFA
401 fluorescence intensity in the absence of AnkR in juvenile and adult mice. This is notable since
402 mice lacking four PNN components (TnC, TnR, and the CSPGs Bcan and neurocan) have a
403 significant reduction in PNN structure, area, and WFA fluorescence during development, but
404 PNNs normalize by postnatal day 35 (Gottschling et al., 2019). Thus, loss of AnkR has more
405 profound effects on maintenance of PNNs than even removing components of the PNNs
406 themselves. This suggests that although AnkR is not necessary for the assembly of PNNs, the
407 receptors responsible for PNN maintenance converge on AnkR (**Fig. 7**). Nevertheless, since
408 PNNs still assemble in the absence of AnkR, other AnkR-independent PNN assembly
409 mechanisms must also exist.

410

411 **AnkR, PNNs, and psychiatric disease**

412 Mice lacking AnkR in GABAergic interneurons showed reduced anxiety in both the open
413 field and elevated plus maze tests. Increased anxiety has been correlated with increased PNN
414 density (Murthy et al., 2019). Conversely, the selective serotonin reuptake inhibitor (SSRI)
415 fluoxetine reduces anxiety as well as PNN density (Ohira et al., 2013). The results of these
416 studies are consistent with our observation that *Ank1^{F/F};Dlx5/6-Cre* mice have both reduced
417 anxiety and a significant reduction in PNN density (**Fig. 7**). Some studies have reported large
418 reductions in PNNs throughout the brains of patients with schizophrenia (Berretta, 2012;
419 Mauney et al., 2013). Multiple GWAS studies implicate *ANK1* as a schizophrenia-associated
420 gene (Aberg et al., 2013; Fromer et al., 2014; Schizophrenia Working Group of the Psychiatric
421 Genomics, 2014), and several of the top candidates for AnkR-interacting proteins identified in
422 our mass spectrometry analysis (e.g. *Myh11*, *Kif1a*, *Itsn1*, and *Slc25a12*) are also schizophrenia-
423 associated genes (Fromer et al., 2014; Schizophrenia Working Group of the Psychiatric
424 Genomics, 2014); *Kv3.1b* is also reduced in patients with schizophrenia (Yanagi et al., 2014).

425 Thus, dysregulation of *ANK1*, leading to reduced AnkR, Kv3.1b, and PNN density, may be a
426 common pathomechanism in psychiatric disease. Intriguingly, the expression of Kv3.1b in
427 schizophrenic patients is corrected by antipsychotic drugs (Yanagi et al., 2014). It will be
428 interesting to determine if antipsychotic drugs similarly affect AnkR protein levels or PNNs.

429

430 **AnkR recruits Kv3.1b to the neuronal membrane**

431 Loss of AnkR from GABAergic interneurons significantly altered their intrinsic and firing
432 properties, suggesting disrupted K⁺ channel function. However, the changes in excitability may
433 also reflect loss of both Kv3.1b K⁺ channels and reduced PNNs, since *Bcan*-deficient mice have
434 similar changes in the excitability of their GABAergic interneurons (Favuzzi et al., 2017). We
435 found that AnkR interacts directly with Kv3.1b and is required to maintain Kv3.1b in GABAergic
436 neurons. We localized Kv3.1b's AnkR-binding motif to 6 residues in its C-terminus: EDCPHI.
437 This motif is different than the previously characterized pan ankyrin-binding motifs present in
438 all Na⁺ channels (Garrido et al., 2003) and L1CAMs (Garver et al., 1997; Tuvia et al., 1997). In
439 contrast, there is specificity among the ankyrin-binding capacities of different K⁺ channels:
440 AnkR interacts with Kv3.1b and is both necessary and sufficient to induce Kv3.1b clustering in
441 the soma of GABAergic interneurons and a subset of CNS nodes of Ranvier, while AnkG binds
442 Kv7.2/3 and is necessary and sufficient for its clustering at AIS and nodes of Ranvier. Although
443 the Kv7.2/3 motif is highly homologous to the Na⁺ channel ankyrin-binding motif, AnkR does
444 not cluster Kv7.2/3 (Wang et al., 2018). When Kv3.1b is present at nodes, it is associated with
445 AnkR. A nearly identical motif is also present in Kv3.3. Like Kv3.1b, Kv3.3 is enriched in Pv⁺
446 interneurons in the forebrain, hippocampus, deep cerebellar nuclei and Purkinje neurons in the
447 cerebellum (Chang et al., 2007); these same cells also express high levels of AnkR (Kordeli and
448 Bennett, 1991). Although one previous study suggested Kv3.3 is not found at nodes (Chang et
449 al., 2007), our results show that CNS nodes with AnkR have both Kv3.1b and Kv3.3, most likely
450 as heterotetramers. Thus, K⁺ channel diversity among nodes of Ranvier is dictated by the
451 specific ankyrin scaffolds present at nodes.

452

453 **AnkR and Alzheimer's disease**

454 A number of epigenome-wide association studies in Alzheimer's disease patients
455 consistently report neuropathology-associated DNA hypermethylation of *ANK1* (De Jager et al.,
456 2014; Higham et al., 2019; Lunnon et al., 2014; Smith et al., 2019a; Smith et al., 2019b).
457 However, the consequence of this hypermethylation for AnkR protein expression is unknown.
458 Experiments in APP/PS1 mice also report significant reductions in Kv3.1b (Boda et al., 2012).
459 Since Kv3.1b levels in GABAergic neurons depend on AnkR, reduced expression of AnkR in the
460 AD brain could result in altered neuronal excitability or circuit function due to the decreased
461 levels of Kv3.1b. Similarly, PNN density has been reported to be reduced in both human AD
462 brains and brains from the 5xFAD mouse model of AD (Crapser et al., 2020). Although these
463 studies suggested that activation of microglia disrupted PNNs, our experiments show that
464 another mechanism could be reduced expression of AnkR. PNNs are thought to protect against
465 neurodegeneration since the loss of PNNs renders neurons more susceptible to accumulation
466 of neurofibrillary tangles comprising phosphorylated tau, and lipofuscin (Suttkus et al., 2016a;
467 Suttkus et al., 2016b), and neurons without PNNs are more susceptible to A β 1-42 toxicity
468 (Miyata et al., 2007). Thus, reduced AnkR expression may decrease PNN density, thereby
469 rendering neurons more susceptible to injury in AD.

470 Since mutations in AnkR cause severe hemolytic anemia, its role in the nervous system
471 has mostly been ignored. However, our results demonstrate that AnkR is much more than just
472 red blood cell ankyrin. Our studies reveal AnkR's critical role in fast-spiking GABAergic
473 interneurons, its interacting proteins, and show that AnkR is necessary for normal interneuron
474 function.

475

476 **ACKNOWLEDGEMENTS**

477 The work reported here was supported by the following research grants from the National
478 institutes of Health: R01 NS044916 (MNR), R01 GM103481 (ALB), R01 MH117089 (MX), R01
479 NS100893 (MX), F31 NS100300 (SRS), F30 MH118804 (CML), RF1 NS118584 (MDC). This work
480 was also supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
481 (ALB and MNR), the HMH Clinician Scientist Award (MDC), and a Houston Methodist
482 Hospital/Baylor College of Medicine collaborative pilot grant in Alzheimer's disease and related

483 dementias. CML is part of the Baylor College of Medicine Medical Scientist Training Program
484 and McNair MD/PhD Student Scholars supported by the McNair Medical Institute at the Robert
485 and Janice McNair Foundation. MX is a Caroline DeLuca Scholar.

486

487 **AUTHOR CONTRIBUTIONS**

488 Conceptualization, Methodology, Validation, Data Curation, Investigation, and Writing –
489 Original Draft and Editing, S.R.S; Methodology, Data Curation, Investigation, and Writing –
490 Original Draft and Editing, C.M.L; Investigation L.H.T., S.N., and Y.O.; Methodology, Data
491 Curation, Writing – Original Draft and Editing, A.S.A; Data Curation, Resources, and Writing –
492 Review and Editing, J.O-P.; Resources, Supervision, Funding Acquisition, and Writing – Review
493 and Editing, A.L.B., Methodology, Investigation, Funding Acquisition, and Writing – Review and
494 Editing, M.D.C; Methodology, Supervision, Funding Acquisition, and Writing – Review and
495 Editing, M.X.; Conceptualization, Methodology, Data Curation, Funding Acquisition, Writing –
496 Original Draft and Editing, and Project Administration, M.N.R.

497

498 **DECLARATION OF INTERESTS**

499 The authors declare no competing financial interests

500

501 MATERIALS AND METHODS

502 **Animals.** AnkR conditional knockout mice were generated using cell-type-specific Cre-mediated
503 deletion of the *Ank1* gene. The targeting construct was designed by introducing *loxP* sites
504 flanking exons 26 and 27 of *Ank1*, upstream of the spectrin binding domain. The Cre-mediated
505 removal of these exons will cause a frame-shift mutation resulting in a premature stop codon in
506 exon 28. Forward primer: 5'-GGG AAA CTC CAC AGA GCC TGA CGG GTC AGT-3', Reverse primer:
507 5'-GGC GTC CCT ATG TTC CAT CCT ATA GAT GAC T-3'. Generation of the target construct, ES
508 cell electroporation, colony selection, blastocyst injection, and generation of chimeric mice
509 were a service of the University of Rochester Medical Center Transgenic Core Facility. The
510 strategy is similar to that successfully used to create the *Ank2* and *Ank3* floxed mice where *loxP*
511 sites flank exons 23/24 and 22/23, respectively(Chang et al., 2014; Ho et al., 2014). *Ank1*^{F/F} mice
512 were generated and backcrossed to C57BL/6 (IMSR Cat# JAX:000664, RRID:IMSR_JAX:000664)
513 for at least four generations before being crossed to *Nestin-Cre* transgenic mice (IMSR Cat#
514 JAX:003771, RRID:IMSR_JAX:003771), *Dlx5/6-Cre* transgenic mice (IMSR Cat# JAX:008199,
515 RRID:IMSR_JAX:008199). *Ank1*^{pale/pale} mice were obtained from Jackson Laboratory (IMSR Cat#
516 JAX:009157, RRID:IMSR_JAX:009157). Since germline recombination has been found to occur in
517 these Cre lines(Luo et al., 2020), immunostaining using anti-AnkR antibodies was used as a
518 secondary confirmation of genotype. *Ank3*^{F/F} mice (IMSR Cat# JAX:029797,
519 RRID:IMSR_JAX:029797) were crossed with *ChAT-Cre* transgenic mice (IMSR Cat# JAX:006410,
520 RRID:IMSR_JAX:006410). Both male and female mice were used in our studies. All experiments
521 were conducted in compliance with the National Institutes of Health Guide for the Care and Use
522 of Laboratory Animals and were approved by the Animal Care and Use Committee at Baylor
523 College of Medicine.

524

525 **Blood transfusion and bone marrow transplant in *Ank1*^{pale/pale} animals.** The *pale* mutation in
526 *Ank1* results in severe anemia characterized by pale skin tone at birth and death within one to
527 two weeks of age(Ho et al., 2014). We performed a blood transfusion at P1 and subsequent
528 bone marrow transplant at P30 which enabled *Ank1*^{pale/pale} animals to survive into adulthood.
529 Animals received a 5mL/kg body weight external jugular vein blood transfusion at P1, and

530 5mL/kg bone marrow transplant into the tail vein at P30. Blood was collected from the male
531 breeding mouse and washed with two-times volume of saline prior centrifugated at 700Xg for
532 20 min at 4°C to remove excess plasma and debris. Bone marrow was isolated from the tibia
533 and femur of close genealogical donor mice. In brief, bones were extracted and placed in 3mL
534 2% fetal bovine serum (FBS) HBSS (without Ca²⁺ and Mg²⁺). Marrow was exposed by cutting
535 with sterile scissors and a 25 gauge needle and 3mL syringe were used to expunge the marrow
536 into a sterile 6cm dish with 2% FBS HBSS on ice. Cells were then filtered through 1 cm² 100 μm
537 nylon mesh into a 5mL FACS tube. Cells were counted and diluted to an injection concentration
538 of 3 million cells/100 μL volume. Throughout life, all animals were closely monitored for
539 changes in weight and behavior.

540

541 **Behavioral Tests.** Mice aged to 9-14 weeks were handled for 3 days prior to the start of testing.
542 Animals began with the open field assessment followed by the elevated plus maze to assess
543 locomotor activity and anxiety. The open field assessment was conducted in white acrylic open-
544 top boxes (46 x 46 x 38cm) in a room lit by indirect white light for 30 minutes. Following this,
545 animals were given 2-3 hours rest in their home cages. The elevated plus maze assessment was
546 then conducted on an elevated platform for 10 minutes. Activity for these tasks was recorded
547 and analyzed using the ANY-maze Video Tracking System version 4.99v (Stoelting Co, Wood
548 Dale, IL).

549

550 **Antibodies.** The primary antibodies used here include: mouse monoclonal antibodies against
551 AnkR (UC Davis/NIH NeuroMab Facility Cat# 75-380, RRID:AB_2491109), β1 spectrin (UC
552 Davis/NIH NeuroMab Facility Cat# 73-374, RRID:AB_2315814), AnkG (UC Davis/NIH NeuroMab
553 Facility Cat# 73-146, RRID:AB_10697718), parvalbumin (UC Davis/NIH NeuroMab Facility Cat#
554 73-455, RRID:AB_2629420), actin (Millipore Cat# MAB1501, RRID:AB_2223041), tenascinR (R
555 and D Systems Cat# MAB1624, RRID:AB_2207001), aggrecan (Millipore Cat# AB1031,
556 RRID:AB_90460), brevican (UC Davis/NIH NeuroMab Facility Cat# 75-294, RRID:AB_2315824),
557 NrCAM (R and D Systems Cat# MAB2034, RRID:AB_2267411), Kv3.1b (UC Davis/NIH NeuroMab
558 Facility Cat# N16B/8, RRID:AB_2750730 and Thermo Fisher Cat# MA5-27684,

559 RRID:AB_2735238), Kv3.3 (Antibodies-Online Cat# ABIN572016, RRID:AB_10782137), Kv7.2
560 (James Trimmer, University of California at Davis Cat# N26A/23, RRID:AB_2750761), Flag-tag or
561 DDDDK-tag (MBL International Cat# M185-3L, RRID:AB_11123930); rabbit polyclonal antibodies
562 against AnkR(Ho et al., 2014) (RRID:AB_2833096), Ank1 (Thermo Fisher Scientific Cat# PA5-
563 63372, RRID:AB_2638015), neurofilament M (Millipore Cat# AB1987, RRID:AB_91201),
564 parvalbumin (Novus Cat# NB120-11427, RRID:AB_791498), versican (Millipore Cat# AB1032,
565 RRID:AB_11213831), PlexinA4 (Abcam Cat# ab39350, RRID:AB_944890), and neuropilin-1
566 (GeneTex Cat# GTX16786, RRID:AB_422398), Kv3.1b (Alomone Labs Cat# APC-014,
567 RRID:AB_2040166), Kv3.3 (Alomone Labs Cat# APC-102, RRID:AB_2040170), GFP (Thermo
568 Fisher Scientific, Cat# A-11122, RRID: AB_221569); and chicken polyclonal antibody against
569 Neurofascin (R and D Systems Cat# AF3235, RRID:AB_10890736). Wisteria Floribunda lectins
570 used were: Fluorescein labeled (Vector Laboratories Cat# FL-1351, RRID:AB_2336875 and
571 Bioworld Cat# 21761065-1, RRID:AB_2833087), and Texas-Red (EY Laboratories Cat# F-3101-1,
572 RRID:AB_2315605). Secondary antibodies were purchased from Jackson ImmunoResearch
573 Laboratories or Life Technologies (IgG specific mouse antibodies). We encourage researchers to
574 determine the optimal antibody dilutions for themselves as varying tissue treatment can affect
575 staining conditions.

576

577 **Immunofluorescence.** Animals were transcardially saline perfused to reduce red blood cells,
578 then brains, spinal cords and roots were dissected and fixed in 4% paraformaldehyde (1 hour
579 for brains and 30 min for spinal cords and roots) on ice and subsequently immersed in 20%
580 sucrose overnight at 4°C. Tissue was embedded in Tissue-Tek OCT (Sakura Finetek 4583)
581 mounting medium, and frozen on dry ice. Brains were sectioned at 25 µm thickness, ventral
582 roots at 14 µm thickness, and spinal cords were sectioned at 18 µm thickness using a cryostat
583 (Thermo Fisher Scientific Cryostar NX70). Sections were placed on 1% bovine gelatin precoated
584 coverslips (Thermo Fisher Scientific). Sections were blocked with 10% normal goat serum in
585 0.1M phosphate buffer (PB) with 0.3% Triton X-100 for 1 hour at room temperature. Primary
586 antibodies diluted in the blocking buffer and incubated at room temperature overnight, then

587 sections were washed with blocking buffer. Secondary antibodies and lectins were incubated at
588 room temperature for 2 hours and washed with 0.1M PB.

589 For immunostaining of human tissues, sections were deparaffinized and rehydrated
590 through a series of alcohols and water. Heat-based antigen retrieval was performed using 1×
591 antigen retrieval solution at pH 9 (Agilent Technologies; Santa Clara, CA) for 1 hour (30 min at
592 95C, followed by 30 min on ice). Washes with fresh phosphate-buffered saline with Tween 20
593 (PBS-T) were then performed and PBS with 0.3% Triton X-100 (Sigma, T8787) was applied for 10
594 minutes. After additional washes with PBS-T, slides were blocked with 2.5% horse serum
595 (Vector Laboratories, Burlingame, CA) with 1% Tween 20 (ThermoFisher, BP337) and 0.1% BSA
596 in PBS (Thermo Scientific, 37525). Primary antibody along with the above blocking solution was
597 applied for 1-2 hours at room temperature. Secondary antibodies were applied for 1 hour at
598 room temperature, including Alexa Fluor 555 Anti-Rabbit IgG (1:200; A21429), Alexa Fluor 555
599 Anti-Mouse IgG (1:200; A32727), Alexa Fluor 488 anti-Mouse IgG (1:200; A11001), and Alexa
600 Fluor 488 anti-Rabbit IgG (1:200; A11034) (Alexa Fluor products of ThermoFisher), as
601 appropriate. For double-labeling studies, dilutions of both primary and secondary antibodies
602 were combined in 2.5% horse serum and applied. Slides were mounted using Vectashield
603 Antifade mounting medium with 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories).
604 These studies were carried out with IRB approval from Houston Methodist Hospital
605 (Pro00010377).

606

607 **Image Analysis.** Immunofluorescence labeling was visualized and images were collected on an
608 AxioImager (Carl Zeiss) fitted with an apotome for optical sectioning, and a digital camera
609 (AxioCam; Carl Zeiss). AxioVision (Carl Zeiss) acquisition software was used for collection of
610 images. Images were also collected using a Nikon Eclipse Ni-E microscope fitted with a
611 motorized X-Y stage for acquisition of fields. Stitching of images was performed using NIS-
612 Elements (Nikon). In some instances, linear contrast and brightness adjustments were
613 performed using Adobe Photoshop, or Z-stacks, 3D reconstruction, and cell counts were
614 performed using NIH FIJI/ImageJ. The WFA or Ankr intensity were quantified as previously
615 described(Gottschling et al., 2019; McCloy et al., 2014). In brief, NIH FIJI/ImageJ was used to

616 draw an outline around each cell and circularity, area, mean fluorescence, along with several
617 adjacent background readings were measured. The corrected total cell fluorescence (CTCF) =
618 integrated density – (area of selected cell × mean fluorescence of background readings), was
619 calculated. These measurements were then averaged within and across multiple brain regions.
620 No other processing of the images was performed. Nodes in ventral roots were counted
621 manually. Nodes were determined to have AnkG, AnkR, Kv3.1b, or Kv7.2 if there was
622 immunofluorescence at the nodes. If there was not immunofluorescence, the node was
623 determined to be absent of AnkG, AnkR, Kv3.1b, or Kv7.2. Human immunofluorescence
624 preparations were reviewed by a neuropathologist (MDC). Images were captured in cellSens
625 software 1.13 (Olympus America, Inc.; Center Valley, PA) on an Olympus BX-43 Microscope
626 using a DP71 camera, an enhanced green fluorescent protein (EGFP) FITC/Cy2 filter cube (set
627 number 49002, Olympus; Center Valley, PA), and a CY3/tetramethylrhodamine-isothiocyanate
628 (TRITC) filter cube (set number 49004, Olympus). To examine the intensity and specificity of
629 antibody labeling, slides were first examined separately under DAPI, TRITC, and FITC filters,
630 photographed, and then merged in cellSens. All figures were assembled using Adobe
631 Illustrator.

632

633 **Immunoblotting.** Saline perfused mouse brains were homogenized in homogenization buffer
634 (0.32M sucrose, 5 mM Na₃PO₄, 1 mM NaF, 0.5 mM PMSF, 1 mM Na₃VO₄ and protease
635 inhibitors) in a Dounce homogenizer on ice. Homogenates were then centrifuged at 700Xg for
636 10 min at 4°C to remove nuclei and debris, the supernatants then underwent another
637 centrifugation at 27200Xg for 90 min at 4°C. Pellets were resuspended in homogenization
638 buffer and protein concentrations were measured. The samples were resolved by SDS-PAGE,
639 transferred to nitrocellulose membrane, and immunoblotted with antibodies. Quantification of
640 immunoblots was done using NIH FIJI/ImageJ.

641

642 **Plasmids.** AnkR-GFP and β1 spectrin-Myc constructs were previously described (Ho et al., 2014).
643 The full-length Kv3.1b construct was a gift from Dr. James Trimmer (University of California at
644 Davis). To generate Flag-tagged full-length or truncated Kv3.1b constructs, parts of Kv3.1b were

645 PCR amplified from full-length Kv3.1b and then inserted into p3XFLAG-CMV-7.1 vector. DNA
646 constructs were verified by sequencing (Genewiz).

647

648 **Immunoprecipitation.** Saline perfused mouse brains were homogenized in 20mM HEPES pH
649 7.4, 2mM EDTA and protease inhibitors in a Dounce homogenizer. 1% (v/v) TX-100 was added
650 to homogenates and solubilized on a shaker for 30 min at 37°C. Lysates were then centrifuged
651 at 700Xg for 20 min at 4°C to remove nuclei and debris, the supernatants then underwent
652 another centrifugation at 27200Xg for 60 min at 4°C. Lysates were collected and protein
653 concentrations were measured. The lysates used for immunoprecipitation were prepared by
654 dilution to final protein concentration at 1 mg/ml with lysis buffer (1% (v/v) Triton X-100, 20
655 mM Tris-HCl pH 8.0, 10 mM EDTA, 150 mM NaCl, 10 mM NaN₃ and protease inhibitors).
656 Antibodies were added and samples were rotated overnight at 4°C. Protein A (polyclonal
657 antibodies, Thermo Scientific, 20333) or Protein G (monoclonal antibodies, GE Healthcare, 17-
658 0618-01) agarose beads were washed with 1 ml of lysis buffer three times and then rotated
659 with the lysates for 1 hour at 4 °C. The beads were then collected and washed with 1 ml of ice-
660 cold lysis buffer seven times and subjected to immunoblotting.

661 For immunoprecipitation of full-length or truncated Kv3.1b, plasmids for these proteins
662 were co-transfected with AnkR-GFP in HEK293T cells using PEI Max (Polysciences, 24765)
663 according to the manufacturer's instructions. The media was replaced after 16-20 hours of
664 transfection. Cells were lysed at 48 hours of transfection in lysis buffer (50 mM Tris-HCl, pH 8.0,
665 150 mM NaCl, 0.1% TritonX-100, and 1 mM EDTA with protease inhibitor), and the lysates were
666 centrifuged at 14,000 rpm for 10 min at 4°C. Anti-GFP antibody was mixed with the supernatant
667 and incubated overnight at 4°C. Protein G Mag Sepharose (Cytiva), was first coated with 1
668 mg/ml of BSA in lysis buffer for 1 hour at 4°C and washed 3 times with lysis buffer, and then
669 incubated with the mixture of cell lysate and antibody for 1 hour at 4°C. After being washed 7
670 times with lysis buffer, the beads were eluted with 50 µl of 1× Laemmli sample buffer at 95°C
671 for 5 min. The samples were analyzed by immunoblot using anti-Flag antibody.

672

673 **Mass Spectrometry.** Brain homogenates were prepared as described above before lipid
674 extraction by acetone. Chilled pure acetone was added to homogenate (4:1) then vortexed to
675 precipitate and rotated overnight at 4°C. Samples were then centrifuged at 27200Xg for 10 min
676 at 4°C and washed twice with chilled acetone and water (4:1). The final pellet was air dried and
677 flash frozen on dry ice. Lysates for AnkR immunoprecipitation were prepared as described
678 above, except the final two washes of the beads were 20mM TrisHCl pH8, 2mM CaCl₂. The
679 beads were then collected and flash frozen on dry ice.

680 For digestion, pellets of lipid extracted brain homogenates were resuspended with
681 sonication in 8M guanidinium hydrochloride plus 200 mM ammonium bicarbonate. Protein was
682 reduced by adding 10 mM DTT and incubating at 60°C for 30 min. After that, samples were
683 treated with 20 mM iodoacetamide at room temperature for 30 min and digested with 2%
684 (W/W) Trypsin/LysC mix, mass spectrometry (MS) grade (Promega) for 4 hours at room
685 temperature. Samples were then diluted using 100 mM ammonium bicarbonate so guanidinium
686 hydrochloride concentration was 1M and incubated at 37°C overnight. After this, another 2%
687 W/W aliquot of the digestion enzymes was added, and the digestion was allowed to continue
688 for 4 hours at room temperature. Digested material was recovered using SepPacks C18
689 cartridges (Waters), eluted in 50% acetonitrile 0.1% formic acid, evaporated and resuspended
690 in 0.1% formic acid for mass spectrometry analysis on a QExactive Plus (Thermo Scientific),
691 connected to a NanoAcquity™ Ultra Performance UPLC system (Waters). 2 µg aliquots of the
692 digests were injected in a 75 µm x 15 cm PepMap RSLC C18 EasySpray column (Thermo
693 Scientific) and peptides resolved in 90 min gradients with 0.1% formic acid in water as mobile
694 phase A and 0.1% formic acid in acetonitrile as mobile phase B. MS was operated in data-
695 dependent mode to automatically switch between MS and MS/MS. The top 10 precursor ions
696 with a charge state of 2+ or higher were fragmented by HCD. A dynamic exclusion window was
697 applied which prevented the same m/z from being selected for 30s after its acquisition

698 For digestion of the immunoprecipitated samples, beads were resuspended in 36 µl 10
699 mM DTT in 100mM NH₄HCO₃ and incubated for 30 min at room temperature. After this,
700 iodoacetamide was added to a final concentration of 15 mM and samples incubated for 30
701 additional minutes. 0.5 µg of sequencing grade trypsin (Promega) was added to each sample

702 and incubated at 37°C overnight. Supernatants of the beads were recovered, and beads
703 digested again using 0.5 µg trypsin in 100mM NH₄HCO₃ for 2 hours. Peptides from both
704 consecutive digestions were recovered by solid phase extraction using C18 ZipTips (Millipore),
705 eluted in 2x7 µl aliquots of 50% MeCN 0.1% formic acid, dried and resuspended in 2.5 µl 0.1%
706 formic acid for mass spectrometry analysis. Peptides were separated using a 75 µm x 50 cm
707 PepMap RSLC C18 EasySpray column (Thermo Scientific) using 3 hour gradients with 0.1%
708 formic acid in water as mobile phase A and 0.1% formic acid in acetonitrile as mobile phase B,
709 for analysis in a Orbitrap Lumos Fusion (Thermo Scientific) in positive ion mode. MS was
710 operated in 3 s cycles in data-dependent mode to automatically switch between MS and
711 MS/MS, with a charge state of 2+ or higher were fragmented by HCD. A dynamic exclusion
712 window was applied which prevented the same m/z from being selected for 30s after its
713 acquisition
714 In both cases, peak lists were generated using PAVA in-house software (Guan et al., 2011).
715 Generated peak lists were searched against the *Mus musculus* subset of the UniprotKB
716 database (UniProtKB.2013.6.17 for the full brain samples and UniProtKB.2017.11.01 for lp
717 samples), using Protein Prospector (Clauser et al., 1999) with the following parameters: Enzyme
718 specificity was set as Trypsin, and up to 2 missed cleavages per peptide were allowed.
719 Carbamidomethylation of cysteine residues was allowed as fixed modification. N-acetylation of
720 the N-terminus of the protein, loss of protein N-terminal methionine, pyroglutamate formation
721 from peptide N-terminal glutamines, and oxidation of methionine were allowed as variable
722 modifications. Mass tolerance was 10 ppm in MS and 30 ppm in MS/MS. The false positive rate
723 was estimated by searching the data using a concatenated database which contains the original
724 UniProtKB database, as well as a version of each original entry where the sequence has been
725 randomized. A 1% FDR was permitted at the protein and peptide level.

726

727 **Brain slice electrophysiology.** All electrophysiological experiments were performed and
728 analyzed blind to the genotypes. Mice were anesthetized by an intraperitoneal injection of a
729 ketamine and xylazine mix (80 mg/kg and 16 mg/kg, respectively) and transcardially perfused
730 with cold (0–4°C) slice cutting solution containing 80 mM NaCl, 2.5 mM KCl, 1.3 mM NaH₂PO₄,

731 26 mM NaHCO₃, 4 mM MgCl₂, 0.5 mM CaCl₂, 20 mM D-glucose, 75 mM sucrose and 0.5 mM
732 sodium ascorbate (315 mosmol, pH 7.4, saturated with 95% O₂/5% CO₂). Brains were removed
733 and sectioned in the cutting solution with a VT1200S vibratome (Leica) to obtain 300 μm
734 coronal slices. Slices containing primary somatosensory cortex were collected and incubated in
735 a custom-made interface holding chamber saturated with 95% O₂/5% CO₂ at 34°C for 30 min
736 and then at room temperature for 20 min to 6 hours until they were transferred to the
737 recording chamber. Prior to moving slices to the recording chamber, 500 μl of fluorescein
738 labeled WFA solution (200 mg/ml, in oxygenated cutting solution) was dropped on top of slices
739 in holding chamber and incubated for 30–45 min to label perineuronal nets. After the
740 incubation period slices were rinsed 3-4 times with oxygenated cutting solution before
741 transferring to the recording chamber.

742 Recordings were performed on submerged slices in artificial cerebrospinal fluid (ACSF)
743 containing 119 mM NaCl, 2.5 mM KCl, 1.3 mM NaH₂PO₄, 26 mM NaHCO₃, 1.3 mM MgCl₂, 2.5
744 mM CaCl₂, 20 mM D-glucose and 0.5 mM sodium ascorbate (305 mosmol, pH 7.4, saturated
745 with 95% O₂/5% CO₂, perfused at 3 ml/min) at 32°C. For whole-cell recordings, a K⁺-based
746 pipette solution containing 142 mM K⁺-gluconate, 10 mM HEPES, 1 mM EGTA, 2.5 mM MgCl₂, 4
747 mM ATP-Mg, 0.3 mM GTP-Na, 10 mM Na₂-phosphoCreatine (295 mosmol, pH 7.35) or a Cs⁺-
748 based pipette solution containing 121 mM Cs⁺-methanesulfonate, 10 mM HEPES, 10 mM EGTA,
749 1.5 mM MgCl₂, 4 mM ATP-Mg, 0.3 mM GTP-Na, 10 mM Na₂-phosphoCreatine, and 2 mM
750 QX314-Cl (295 mosmol, pH 7.35) was used. Membrane potentials were not corrected for liquid
751 junction potential (experimentally measured as 12.5 mV for the K⁺-based pipette solution and
752 9.5 mV for the Cs⁺-based pipette solution).

753 Neurons were visualized with video-assisted infrared differential interference contrast
754 imaging and WFA+ neurons were identified by epifluorescence imaging under a water
755 immersion objective (40x, 0.8 numerical aperture) on an upright SliceScope Pro 1000
756 microscope (Scientifica) with an infrared IR-1000 CCD camera (DAGE-MTI). Data were acquired
757 at 10 kHz and low-pass filtered at 4 kHz with an Axon Multiclamp 700B amplifier and an Axon
758 Digidata 1440 Data Acquisition System under the control of Clampex 10.7 (Molecular Devices).

759 Neuronal intrinsic excitability was examined with the K⁺-based pipette solution. The
760 resting membrane potential was recorded in the whole-cell current clamp mode within the first
761 minute after break-in. After balancing the bridge, the input resistance and membrane
762 capacitance were measured by injecting a 500-ms hyperpolarizing current pulse (50–100 pA) to
763 generate a small membrane potential hyperpolarization (2–10 mV) from the resting membrane
764 potential. Depolarizing currents were increased in 5- or 10-pA steps to identify rheobase
765 currents. To generate the current-firing frequency curves, the resting membrane potential of
766 neurons was held at –75 mV and 500-ms depolarizing current pulses were increased by 50 pA
767 steps from 0 to 1450 pA. If depolarization block occurred prior to 1450 pA, then recording was
768 stopped.

769 To record miniature synaptic currents, whole-cell voltage clamp recordings of WFA+
770 cells were performed with the Cs⁺-based pipette solution in ACSF containing 1 μM tetrodotoxin.
771 mEPSCs and mIPSCs were recorded for 2–3 min at the reversal potential for inhibition (–70 mV)
772 and excitation (+10 mV), respectively.

773

774 **Electrophysiology data analysis.** Data were analyzed offline by AxoGraph X (AxoGraph
775 Scientific). The single action potential generated by the rheobase current was used to analyze
776 action potential characteristics. Action potential threshold was defined as the voltage at which
777 the first derivative of voltage over time exceeded 20 V/s. The action potential latency was
778 determined as the time between the onset of current injection and action potential threshold.
779 Action potential amplitude was determined as the voltage difference between the action
780 potential threshold and peak. Action potential half-width was measured as the duration of the
781 action potential at the voltage halfway between the action potential threshold and peak.
782 Afterhyperpolarization (AHP) amplitude was determined as the minimum voltage following the
783 action potential peak subtracted from the action potential threshold. AHP time was determined
784 as the time between action potential threshold and the negative peak of AHP.

785 To analyze spike trains, action potentials were detected using Axograph X event
786 detection with a fixed amplitude template defined by the shape of the action potential. The
787 current-firing frequency curves were generated by measuring the frequency of action

788 potentials for each current injection. Spike frequency adaptation and amplitude adaptation
789 were determined from the spike train evoked by the currents that are 2 times of the action
790 potential threshold currents. Spike frequency adaptation was measured by determining the
791 percent decrease between the inverse of the average of the first five inter-spike intervals and
792 the inverse of the average of the last five inter-spike intervals. Amplitude adaptation was
793 determined by baselining the trace at the action potential threshold for the first action
794 potential and then calculating the percent decrease between the amplitude of the first action
795 potential and the last one. The firing frequency within the first 100 ms of current injection was
796 also determined. Depolarization block current was determined as the minimal current that
797 caused the cell to reach depolarization block during the 500 ms current pulse. If depolarization
798 block was not reached by 1450 pA current injection, 1450 pA was recorded as the value.

799 To detect miniature synaptic events, data were digitally low-pass filtered at 2 kHz offline
800 and events were detected by a scaled-template algorithm (AxoGraph X). The parameters of the
801 template for mEPSCs are: length, 5 ms; baseline, 1.5 ms; amplitude, -2 pA; rise time, 0.2 ms;
802 and decay time, 1 ms with a detection threshold of -3.25 . The parameters of the template for
803 mIPSCs are: length, 10 ms; baseline, 3 ms; amplitude, 2 pA; rise time, 0.27 ms; and decay time,
804 3.7 ms with a detection threshold of 3. The integrated charge per unit time for mEPSC or mIPSC
805 was determined by multiplying the frequency of mEPSC or mIPSC by the average charge of
806 mEPSCs or mIPSCs, respectively.

807

808 **Statistical Analyses.** No statistical methods were used to pre-determine sample sizes, but our
809 sample sizes are similar to those previously reported (Chiang et al., 2018; Ho et al., 2014). Sets
810 of age-matched conditional knockout mice and their controls were randomly collected from the
811 same litter or from two litters that had close dates of birth. Data were collected and processed
812 randomly and were analyzed using Microsoft Excel and GraphPad Prism. Except for
813 perineuronal net quantifications, researchers were not 'blinded' to the conditions of the
814 experiments for data collection and analysis. Unless otherwise stated, unpaired, two-tailed
815 Student's *t*-test was used for statistical analysis. Data distributions were assumed to be normal,

816 but were not formally tested. All error bars are SEM unless otherwise indicated. Significance
817 values indicated in figures are for post hoc comparisons.

818

819

820 REFERENCES

821 Aberg, K.A., Liu, Y., Bukszar, J., McClay, J.L., Khachane, A.N., Andreassen, O.A., Blackwood, D.,
822 Corvin, A., Djurovic, S., Gurling, H., *et al.* (2013). A comprehensive family-based replication
823 study of schizophrenia genes. *JAMA Psychiatry* 70, 573-581.

824 Amor, V., Zhang, C., Vainshtein, A., Zhang, A., Zollinger, D.R., Eshed-Eisenbach, Y., Brophy, P.J.,
825 Rasband, M.N., and Peles, E. (2017). The paranodal cytoskeleton clusters Na(+) channels at
826 nodes of Ranvier. *eLife* 6.

827 Bekku, Y., Rauch, U., Ninomiya, Y., and Oohashi, T. (2009). Brevican distinctively assembles
828 extracellular components at the large diameter nodes of Ranvier in the CNS. *J Neurochem* 108,
829 1266-1276.

830 Bennett, V., and Lorenzo, D.N. (2013). Spectrin- and ankyrin-based membrane domains and the
831 evolution of vertebrates. *Current topics in membranes* 72, 1-37.

832 Bennett, V., and Stenbuck, P.J. (1979). The membrane attachment protein for spectrin is
833 associated with band 3 in human erythrocyte membranes. *Nature* 280, 468-473.

834 Berretta, S. (2012). Extracellular matrix abnormalities in schizophrenia. *Neuropharmacology* 62,
835 1584-1597.

836 Boda, E., Hoxha, E., Pini, A., Montarolo, F., and Tempia, F. (2012). Brain expression of Kv3
837 subunits during development, adulthood and aging and in a murine model of Alzheimer's
838 disease. *J Mol Neurosci* 46, 606-615.

839 Bruckner, G., Brauer, K., Hartig, W., Wolff, J.R., Rickmann, M.J., Derouiche, A., Delpech, B.,
840 Girard, N., Oertel, W.H., and Reichenbach, A. (1993). Perineuronal nets provide a polyanionic,
841 glia-associated form of microenvironment around certain neurons in many parts of the rat
842 brain. *Glia* 8, 183-200.

843 Cabungcal, J.H., Steullet, P., Morishita, H., Kraftsik, R., Cuenod, M., Hensch, T.K., and Do, K.Q.
844 (2013). Perineuronal nets protect fast-spiking interneurons against oxidative stress. *Proc Natl*
845 *Acad Sci U S A* 110, 9130-9135.

846 Carceller, H., Guirado, R., Ripolles-Campos, E., Teruel-Marti, V., and Nacher, J. (2020).
847 Perineuronal Nets Regulate the Inhibitory Perisomatic Input onto Parvalbumin Interneurons
848 and gamma Activity in the Prefrontal Cortex. *J Neurosci* 40, 5008-5018.

849 Carulli, D., Rhodes, K.E., and Fawcett, J.W. (2007). Upregulation of aggrecan, link protein 1, and
850 hyaluronan synthases during formation of perineuronal nets in the rat cerebellum. *J Comp*
851 *Neurol* 501, 83-94.

852 Chang, K.J., Zollinger, D.R., Susuki, K., Sherman, D.L., Makara, M.A., Brophy, P.J., Cooper, E.C.,
853 Bennett, V., Mohler, P.J., and Rasband, M.N. (2014). Glial ankyrins facilitate paranodal axoglial
854 junction assembly. *Nat Neurosci* 17, 1673-1681.

855 Chang, S.Y., Zaghera, E., Kwon, E.S., Ozaita, A., Bobik, M., Martone, M.E., Ellisman, M.H., Heintz,
856 N., and Rudy, B. (2007). Distribution of Kv3.3 potassium channel subunits in distinct neuronal
857 populations of mouse brain. *J Comp Neurol* 502, 953-972.

858 Chiang, A.C.A., Fowler, S.W., Reddy, R., Pletnikova, O., Troncoso, J.C., Sherman, M.A., Lesne,
859 S.E., and Jankowsky, J.L. (2018). Discrete Pools of Oligomeric Amyloid-beta Track with Spatial
860 Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. *Am J Pathol* 188, 739-756.

861 Clauser, K.R., Baker, P., and Burlingame, A.L. (1999). Role of accurate mass measurement (+/-
862 10 ppm) in protein identification strategies employing MS or MS/MS and database searching.
863 *Anal Chem* 71, 2871-2882.

864 Coetzer, T.L., Lawler, J., Liu, S.C., Prchal, J.T., Gualtieri, R.J., Brain, M.C., Dacie, J.V., and Palek, J.
865 (1988). Partial ankyrin and spectrin deficiency in severe, atypical hereditary spherocytosis. *N*
866 *Engl J Med* 318, 230-234.

867 Crapser, J.D., Spangenberg, E.E., Barahona, R.A., Arreola, M.A., Hohsfield, L.A., and Green, K.N.
868 (2020). Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain.
869 *EBioMedicine* 58, 102919.

870 Davis, J.Q., and Bennett, V. (1994). Ankyrin binding activity shared by the
871 neurofascin/L1/NrCAM family of nervous system cell adhesion molecules. *J Biol Chem* 269,
872 27163-27166.

873 De Jager, P.L., Srivastava, G., Lunnon, K., Burgess, J., Schalkwyk, L.C., Yu, L., Eaton, M.L., Keenan,
874 B.T., Ernst, J., McCabe, C., *et al.* (2014). Alzheimer's disease: early alterations in brain DNA
875 methylation at ANK1, BIN1, RHBDL2 and other loci. *Nat Neurosci* 17, 1156-1163.

876 de Lombares, C., Heude, E., Alfama, G., Fontaine, A., Hassouna, R., Vernochet, C., de Chaumont,
877 F., Olivo-Marin, C., Ey, E., Parnaudeau, S., *et al.* (2019). Dlx5 and Dlx6 expression in GABAergic
878 neurons controls behavior, metabolism, healthy aging and lifespan. *Aging (Albany NY)* 11, 6638-
879 6656.

880 de Winter, F., Kwok, J.C., Fawcett, J.W., Vo, T.T., Carulli, D., and Verhaagen, J. (2016). The
881 Chemorepulsive Protein Semaphorin 3A and Perineuronal Net-Mediated Plasticity. *Neural Plast*
882 2016, 3679545.

883 Devaux, J., Alcaraz, G., Grinspan, J., Bennett, V., Joho, R., Crest, M., and Scherer, S.S. (2003).
884 Kv3.1b is a novel component of CNS nodes. *J Neurosci* 23, 4509-4518.

885 Dzhashiashvili, Y., Zhang, Y., Galinska, J., Lam, I., Grumet, M., and Salzer, J.L. (2007). Nodes of
886 Ranvier and axon initial segments are ankyrin G-dependent domains that assemble by distinct
887 mechanisms. *J Cell Biol* 177, 857-870.

888 Favuzzi, E., Marques-Smith, A., Deogracias, R., Winterflood, C.M., Sanchez-Aguilera, A.,
889 Mantoan, L., Maeso, P., Fernandes, C., Ewers, H., and Rico, B. (2017). Activity-Dependent Gating
890 of Parvalbumin Interneuron Function by the Perineuronal Net Protein Brevican. *Neuron* 95,
891 639-655 e610.

892 Fawcett, J.W., Oohashi, T., and Pizzorusso, T. (2019). The roles of perineuronal nets and the
893 perinodal extracellular matrix in neuronal function. *Nat Rev Neurosci* 20, 451-465.

894 Fromer, M., Pocklington, A.J., Kavanagh, D.H., Williams, H.J., Dwyer, S., Gormley, P., Georgieva,
895 L., Rees, E., Palta, P., Ruderfer, D.M., *et al.* (2014). De novo mutations in schizophrenia implicate
896 synaptic networks. *Nature* 506, 179-184.

897 Garrido, J.J., Giraud, P., Carlier, E., Fernandes, F., Moussif, A., Fache, M.P., Debanne, D., and
898 Dargent, B. (2003). A targeting motif involved in sodium channel clustering at the axonal initial
899 segment. *Science* 300, 2091-2094.

900 Garver, T.D., Ren, Q., Tuvia, S., and Bennett, V. (1997). Tyrosine phosphorylation at a site highly
901 conserved in the L1 family of cell adhesion molecules abolishes ankyrin binding and increases
902 lateral mobility of neurofascin. *J Cell Biol* 137, 703-714.

903 Gasparoni, G., Bultmann, S., Lutsik, P., Kraus, T.F.J., Sordon, S., Vlcek, J., Dietinger, V.,
904 Steinmaurer, M., Haider, M., Mulholland, C.B., *et al.* (2018). DNA methylation analysis on
905 purified neurons and glia dissects age and Alzheimer's disease-specific changes in the human
906 cortex. *Epigenetics Chromatin* 11, 41.

907 Gottschling, C., Wegrzyn, D., Denecke, B., and Faissner, A. (2019). Elimination of the four
908 extracellular matrix molecules tenascin-C, tenascin-R, brevican and neurocan alters the ratio of
909 excitatory and inhibitory synapses. *Scientific reports* 9, 13939.

910 Guan, S., Price, J.C., Prusiner, S.B., Ghaemmaghami, S., and Burlingame, A.L. (2011). A data
911 processing pipeline for mammalian proteome dynamics studies using stable isotope metabolic
912 labeling. *Molecular & cellular proteomics : MCP* 10, M111 010728.

913 Hartig, W., Derouiche, A., Welt, K., Brauer, K., Grosche, J., Mader, M., Reichenbach, A., and
914 Bruckner, G. (1999). Cortical neurons immunoreactive for the potassium channel Kv3.1b
915 subunit are predominantly surrounded by perineuronal nets presumed as a buffering system
916 for cations. *Brain Res* 842, 15-29.

917 Hedstrom, K.L., Ogawa, Y., and Rasband, M.N. (2008). AnkyrinG is required for maintenance of
918 the axon initial segment and neuronal polarity. *J Cell Biol* 183, 635-640.

919 Hedstrom, K.L., Xu, X., Ogawa, Y., Frischknecht, R., Seidenbecher, C.I., Shrager, P., and Rasband,
920 M.N. (2007). Neurofascin assembles a specialized extracellular matrix at the axon initial
921 segment. *J Cell Biol* 178, 875-886.

922 Higham, J.P., Malik, B.R., Buhl, E., Dawson, J.M., Ogier, A.S., Lunnon, K., and Hodge, J.J.L. (2019).
923 Alzheimer's Disease Associated Genes Ankyrin and Tau Cause Shortened Lifespan and Memory
924 Loss in *Drosophila*. *Frontiers in cellular neuroscience* 13, 260.

925 Ho, T.S., Zollinger, D.R., Chang, K.J., Xu, M., Cooper, E.C., Stankewich, M.C., Bennett, V., and
926 Rasband, M.N. (2014). A hierarchy of ankyrin-spectrin complexes clusters sodium channels at
927 nodes of Ranvier. *Nat Neurosci* 17, 1664-1672.

928 Huang, C.Y., Zhang, C., Ho, T.S., Oses-Prieto, J., Burlingame, A.L., Lalonde, J., Noebels, J.L.,
929 Leterrier, C., and Rasband, M.N. (2017a). α 1 Spectrin Forms a Periodic Cytoskeleton at the
930 Axon Initial Segment and Is Required for Nervous System Function. *J Neurosci* 37, 11311-11322.

931 Huang, C.Y., Zhang, C., Zollinger, D.R., Leterrier, C., and Rasband, M.N. (2017b). An α 1
932 Spectrin-Based Cytoskeleton Protects Large-Diameter Myelinated Axons from Degeneration. *J*
933 *Neurosci* 37, 11323-11334.

934 Irvine, S.F., and Kwok, J.C.F. (2018). Perineuronal Nets in Spinal Motoneurons: Chondroitin
935 Sulphate Proteoglycan around Alpha Motoneurons. *Int J Mol Sci* 19.

936 Kordeli, E., and Bennett, V. (1991). Distinct ankyrin isoforms at neuron cell bodies and nodes of
937 Ranvier resolved using erythrocyte ankyrin-deficient mice. *J Cell Biol* 114, 1243-1259.

938 Kwok, J.C., Dick, G., Wang, D., and Fawcett, J.W. (2011). Extracellular matrix and perineuronal
939 nets in CNS repair. *Dev Neurobiol* 71, 1073-1089.

940 Lau, D., Vega-Saenz de Miera, E.C., Contreras, D., Ozaita, A., Harvey, M., Chow, A., Noebels, J.L.,
941 Paylor, R., Morgan, J.I., Leonard, C.S., and Rudy, B. (2000). Impaired fast-spiking, suppressed
942 cortical inhibition, and increased susceptibility to seizures in mice lacking Kv3.2 K⁺ channel
943 proteins. *J Neurosci* 20, 9071-9085.

944 Liu, C.H., Seo, R., Ho, T.S., Stankewich, M., Mohler, P.J., Hund, T.J., Noebels, J.L., and Rasband,
945 M.N. (2020a). β spectrin-dependent and domain specific mechanisms for Na⁽⁺⁾ channel
946 clustering. *eLife* 9.

947 Liu, C.H., Stevens, S.R., Teliska, L.H., Stankewich, M., Mohler, P.J., Hund, T.J., and Rasband, M.N.
948 (2020b). Nodal β spectrins are required to maintain Na⁽⁺⁾ channel clustering and axon
949 integrity. *eLife* 9.

950 Lunnon, K., Smith, R., Hannon, E., De Jager, P.L., Srivastava, G., Volta, M., Troakes, C., Al-Sarraj,
951 S., Burrage, J., Macdonald, R., *et al.* (2014). Methylomic profiling implicates cortical
952 deregulation of ANK1 in Alzheimer's disease. *Nat Neurosci* 17, 1164-1170.

953 Luo, L., Ambrozkiwicz, M.C., Benseler, F., Chen, C., Dumontier, E., Falkner, S., Furlanis, E.,
954 Gomez, A.M., Hoshina, N., Huang, W.H., *et al.* (2020). Optimizing Nervous System-Specific Gene
955 Targeting with Cre Driver Lines: Prevalence of Germline Recombination and Influencing Factors.
956 *Neuron* 106, 37-65 e35.

957 Lux, S.E., Tse, W.T., Menninger, J.C., John, K.M., Harris, P., Shalev, O., Chilcote, R.R., Marchesi,
958 S.L., Watkins, P.C., Bennett, V., and et al. (1990). Hereditary spherocytosis associated with
959 deletion of human erythrocyte ankyrin gene on chromosome 8. *Nature* 345, 736-739.

960 Mauney, S.A., Athanas, K.M., Pantazopoulos, H., Shaskan, N., Passeri, E., Berretta, S., and Woo,
961 T.U. (2013). Developmental pattern of perineuronal nets in the human prefrontal cortex and
962 their deficit in schizophrenia. *Biological psychiatry* 74, 427-435.

963 McCann, S.R., and Jacob, H.S. (1976). Spinal cord disease in hereditary spherocytosis: report of
964 two cases with a hypothesized common mechanism for neurologic and red cell abnormalities.
965 *Blood* 48, 259-263.

966 McCloy, R.A., Rogers, S., Caldon, C.E., Lorca, T., Castro, A., and Burgess, A. (2014). Partial
967 inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. *Cell Cycle* 13,
968 1400-1412.

969 Michaely, P., and Bennett, V. (1995). Mechanism for binding site diversity on ankyrin.
970 Comparison of binding sites on ankyrin for neurofascin and the Cl⁻/HCO₃⁻ anion exchanger. *J*
971 *Biol Chem* 270, 31298-31302.

972 Miya, K., Shimojima, K., Sugawara, M., Shimada, S., Tsuru, H., Harai-Tanaka, T., Nakaoka, S.,
973 Kanegane, H., Miyawaki, T., and Yamamoto, T. (2012). A de novo interstitial deletion of 8p11.2
974 including ANK1 identified in a patient with spherocytosis, psychomotor developmental delay,
975 and distinctive facial features. *Gene* 506, 146-149.

976 Miyata, S., Nishimura, Y., and Nakashima, T. (2007). Perineuronal nets protect against amyloid
977 beta-protein neurotoxicity in cultured cortical neurons. *Brain Res* 1150, 200-206.

978 Murthy, S., Kane, G.A., Katchur, N.J., Lara Mejia, P.S., Obiofuma, G., Buschman, T.J., McEwen,
979 B.S., and Gould, E. (2019). Perineuronal Nets, Inhibitory Interneurons, and Anxiety-Related
980 Ventral Hippocampal Neuronal Oscillations Are Altered by Early Life Adversity. *Biological*
981 *psychiatry* 85, 1011-1020.

982 Nakamura, F., Kalb, R.G., and Strittmatter, S.M. (2000). Molecular basis of semaphorin-
983 mediated axon guidance. *J Neurobiol* 44, 219-229.

984 Ohira, K., Takeuchi, R., Iwanaga, T., and Miyakawa, T. (2013). Chronic fluoxetine treatment
985 reduces parvalbumin expression and perineuronal nets in gamma-aminobutyric acidergic
986 interneurons of the frontal cortex in adult mice. *Mol Brain* 6, 43.

987 Pan, Z., Kao, T., Horvath, Z., Lemos, J., Sul, J.-Y., Cranstoun, S.D., Bennett, M.V., Scherer, S.S.,
988 and Cooper, E.C. (2006). A common ankyrin-G-based mechanism retains KCNQ and Nav
989 channels at electrically active domains of the axon. *J Neurosci* 26, 2599-2613.

990 Peters, L.L., Birkenmeier, C.S., Bronson, R.T., White, R.A., Lux, S.E., Otto, E., Bennett, V., Higgins,
991 A., and Barker, J.E. (1991). Purkinje cell degeneration associated with erythroid ankyrin
992 deficiency in nb/nb mice. *J Cell Biol* 114, 1233-1241.

993 Rowlands, D., Lensjo, K.K., Dinh, T., Yang, S., Andrews, M.R., Hafting, T., Fyhn, M., Fawcett, J.W.,
994 and Dick, G. (2018). AggreCAN Directs Extracellular Matrix-Mediated Neuronal Plasticity. *J*
995 *Neurosci* 38, 10102-10113.

996 Schizophrenia Working Group of the Psychiatric Genomics, C. (2014). Biological insights from
997 108 schizophrenia-associated genetic loci. *Nature* 511, 421-427.

998 Scotland, P., Zhou, D., Benveniste, H., and Bennett, V. (1998). Nervous system defects of
999 AnkyrinB (-/-) mice suggest functional overlap between the cell adhesion molecule L1 and 440-
1000 kD AnkyrinB in premyelinated axons. *J Cell Biol* 143, 1305-1315.

1001 Sedgwick, S.G., and Smerdon, S.J. (1999). The ankyrin repeat: a diversity of interactions on a
1002 common structural framework. *Trends Biochem Sci* 24, 311-316.

1003 Smith, A.R., Smith, R.G., Burrage, J., Troakes, C., Al-Sarraj, S., Kalaria, R.N., Sloan, C., Robinson,
1004 A.C., Mill, J., and Lunnon, K. (2019a). A cross-brain regions study of ANK1 DNA methylation in
1005 different neurodegenerative diseases. *Neurobiology of aging* 74, 70-76.

1006 Smith, A.R., Smith, R.G., Pishva, E., Hannon, E., Roubroeks, J.A.Y., Burrage, J., Troakes, C., Al-
1007 Sarraj, S., Sloan, C., Mill, J., *et al.* (2019b). Parallel profiling of DNA methylation and
1008 hydroxymethylation highlights neuropathology-associated epigenetic variation in Alzheimer's
1009 disease. *Clin Epigenetics* 11, 52.

1010 Susuki, K., Chang, K.J., Zollinger, D.R., Liu, Y., Ogawa, Y., Eshed-Eisenbach, Y., Dours-
1011 Zimmermann, M.T., Oses-Prieto, J.A., Burlingame, A.L., Seidenbecher, C.I., *et al.* (2013). Three
1012 mechanisms assemble central nervous system nodes of Ranvier. *Neuron* 78, 469-482.

1013 Susuki, K., Zollinger, D.R., Chang, K.J., Zhang, C., Huang, C.Y., Tsai, C.R., Galiano, M.R., Liu, Y.,
1014 Benusa, S.D., Yermakov, L.M., *et al.* (2018). Glial betaII Spectrin Contributes to Paranode
1015 Formation and Maintenance. *J Neurosci* 38, 6063-6075.

1016 Suttkus, A., Holzer, M., Morawski, M., and Arendt, T. (2016a). The neuronal extracellular matrix
1017 restricts distribution and internalization of aggregated Tau-protein. *Neuroscience* 313, 225-235.

1018 Suttkus, A., Morawski, M., and Arendt, T. (2016b). Protective Properties of Neural Extracellular
1019 Matrix. *Mol Neurobiol* 53, 73-82.

1020 Tuvia, S., Garver, T.D., and Bennett, V. (1997). The phosphorylation state of the FIGQY tyrosine
1021 of neurofascin determines ankyrin-binding activity and patterns of cell segregation. *Proc Natl*
1022 *Acad Sci U S A* 94, 12957-12962.

1023 Wang, C.C., Ortiz-Gonzalez, X.R., Yum, S.W., Gill, S.M., White, A., Kelter, E., Seaver, L.H., Lee, S.,
1024 Wiley, G., Gaffney, P.M., *et al.* (2018). betaIV Spectrinopathies Cause Profound Intellectual
1025 Disability, Congenital Hypotonia, and Motor Axonal Neuropathy. *Am J Hum Genet* 102, 1158-
1026 1168.

1027 Wintergerst, E.S., Vogt Weisenhorn, D.M., Rathjen, F.G., Riederer, B.M., Lambert, S., and Celio,
1028 M.R. (1996). Temporal and spatial appearance of the membrane cytoskeleton and perineuronal
1029 nets in the rat neocortex. *Neurosci Lett* 209, 173-176.

1030 Yamada, J., and Jinno, S. (2017). Molecular heterogeneity of aggrecan-based perineuronal nets
1031 around five subclasses of parvalbumin-expressing neurons in the mouse hippocampus. *J Comp*
1032 *Neurol* 525, 1234-1249.


1033 Yanagi, M., Joho, R.H., Southcott, S.A., Shukla, A.A., Ghose, S., and Tamminga, C.A. (2014).
1034 Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with
1035 antipsychotic drugs. *Molecular psychiatry* 19, 573-579.

1036 Zhou, D., Lambert, S., Malen, P.L., Carpenter, S., Boland, L.M., and Bennett, V. (1998). AnkyrinG
1037 is required for clustering of voltage-gated Na channels at axon initial segments and for normal
1038 action potential firing. *J Cell Biol* 143, 1295-1304.

1039

1040


Figure 1



1041 **Figure 1.** AnkR is expressed in select neurons in the cortex and hippocampus.
1042 (A) Immunostaining of coronal mouse brain for AnkR. Arrowhead indicates a red blood cell.
1043 Scalebars, left, 250 μm , right, 20 μm .
1044 (B) Immunoblot of P1, P15, P30, and 6-month C57BL/6 brain homogenates for anti-AnkR and
1045 neurofilament-M (NFM). Quantification of immunoblot in ImageJ by comparison of AnkR to
1046 NFM loading control from three independent duplicate experiments (n=3-4 mice/group).
1047 Samples were normalized to NFM, then compared to 6-month animals.
1048 (C, D) Immunostaining for AnkR (red) and Parvalbumin (Pv, green) in P56 coronal cortex (C, N =
1049 3 mice; n=4495 cells) and coronal hippocampus (D, N = 3 mice; n=1637 cells). Scalebars, 50 μm ;
1050 inset, 10 μm .
1051 (E) Immunostaining of human cortex for AnkR (red) and Parvalbumin (green). Nuclei are
1052 labeled using DAPI (blue). Scalebars, 20 μm .
1053 (F) Schematic of the *Ank1* conditional allele. *loxP* sites (red triangles) flank exons 26 and 27 in
1054 the spectrin binding domain (SBD), after the membrane binding domain (MBD) and before the
1055 regulatory domain (RD). Cre-mediated recombination and removal of exons 26 and 27
1056 generates a premature stop codon in exon 28.
1057 (G) Immunoblot of brain homogenates for anti-AnkR, and Neurofilament-M. Molecular weights
1058 are indicated at right in kDa. All error bars indicate mean \pm SEM.


1059

Supplemental Figure 1




1060 **Supplemental Figure 1.** Ankr immunostaining in *Ank1* conditional knockout mice.
1061 (A) Immunostaining of cortex (top) and hippocampus (bottom) in mice with the indicated
1062 genotypes. Scalebars, 50 μm .
1063 (B) Immunostaining of cortex for Ankr (red) and AnkG (green) in the indicated genotypes.
1064 Scalebars, 20 μm .
1065

Figure 2



1067 **Figure 2.** AnkR interacting proteins.
1068 **(A)** Immunostaining of mouse cortex using antibodies against AnkR (red) and β 1 spectrin
1069 (green). Scalebar, 20 μ m.
1070 **(B)** Immunoblot of β 1 spectrin, AnkR, and Caspr immunoprecipitation reactions using
1071 antibodies against AnkR and β 1 spectrin. IP, immunoprecipitation; IB, immunoblot.
1072 **(C)** Immunoblot of control and AnkR-deficient mouse brains using antibodies against β 1
1073 spectrin, AnkR, and neurofilament-M (NFM). Quantification of the β 1 spectrin immunoblots
1074 normalized to NFM. Error bars indicate mean \pm SEM. N=6.
1075 **(D)** Top AnkR-interacting candidates. Circle size corresponds to the mean PSM from IP mass
1076 spectrometry. Concentric circles radiating from *Ank1* correspond to % reduction in PSMs from
1077 AnkR knockout mouse compared to control. Identified proteins are organized according to
1078 their putative functions.
1079 **(E-H)** Immunostaining of mouse cortex using antibodies against AnkR (red) and TnR (green, **E**),
1080 Bcan (green, **F**), Acan (green, **G**), and Vcan (green, **H**). Scalebars, 20 μ m.
1081 **(I)** Immunostaining of mouse cortex and hippocampus using antibodies against AnkR (red) and
1082 fluorescent-labeled WFA (green). Scalebars, 250 μ m (top) and 20 μ m (bottom).
1083 **(J)** Immunostaining of control (left) and AnkR-deficient mouse brain (right) using antibodies
1084 against AnkR (red) and NrCAM (green). Scalebars, 50 μ m.
1085 **(K)** Immunoblot of NrCAM, AnkR, and Caspr immunoprecipitation reactions using antibodies
1086 against AnkR (top) and NrCAM (bottom).
1087 **(L)** Immunoblot of PlexinA4, AnkR, and Caspr immunoprecipitation reactions using antibodies
1088 against AnkR (top). Immunoblot of Nrp1, AnkR, and Caspr immunoprecipitation reactions using
1089 antibodies against AnkR (bottom).

Supplemental Figure 2




1090

1091

1092 **Supplemental Figure 2.** AnkR interacting proteins.
1093 **(A, B)** Immunostaining of cortex **(A)** and hippocampus **(B)** in control and AnkR-deficient mouse
1094 brain using antibodies against AnkR (red), β 1 spectrin (green), and the nuclear marker Hoechst.
1095 Scale bars, 50 μ m.
1096 **(C)** Proteomics strategy to identify AnkR-interacting proteins. PSM, peptide spectral match.
1097 **(D, E)** Immunostaining of cortex **(D)** and hippocampus **(E)** using antibodies against AnkR (red)
1098 and NrCAM (green). Arrowheads in **(E)** indicate AnkR⁺/NrCAM⁺ neurons. Scalebars, 20 μ m **(D)**,
1099 50 μ m **(E)**.
1100 **(F)** Immunofluorescence of hippocampus using fluorescent WFA (red) and antibodies against
1101 NrCAM (green). Arrowheads indicate WFA⁺ neurons. Scalebar, 25 μ m.
1102 **(G, H)** Immunostaining of caudoputamen in control and AnkR-deficient mouse brain using
1103 fluorescent WFA (red) and antibodies against NrCAM (green). Arrowheads indicate WFA⁺
1104 neurons. Scalebars, 50 μ m.
1105 **(I)** Staining of deep cerebellar nuclei using antibodies against Nrp1 (green) and AnkR (red).
1106 Scalebar, 100 μ m.
1107

Figure 3




1108

1109

1110 **Figure 3.** AnkR maintains perineuronal net density and structure.
1111 (A) Fluorescent WFA labeling of PNNs in coronal sections of cortex and hippocampus in one-
1112 month-old mice. Genotypes of the respective mice are indicated. Boxed regions are shown to
1113 the right. Scalebars, 250 μm and 100 μm .
1114 (B) Quantification of colocalization between WFA and Pv labeling per unit area (UA) in
1115 hippocampus and cortex. N=3 mice/group.
1116 (C) Corrected total cell fluorescence (CTCF) in hippocampus (HPC) and cortex (CTX). N=3
1117 mice/group, n=230 cells/animal.
1118 (D) Semi-quantitative analysis of high magnification WFA showing increased hole size and
1119 disruption of PNNs in retrosplenial (RSP) cortex of 1-month mice. N=3 mice/group, n=20
1120 cells/animal.
1121 (E) Fluorescent WFA label of PNNs in RSP cortex of one-month-old mice. Genotypes of the
1122 respective mice are indicated. Scalebars, 5 μm .
1123 (F) Fluorescent WFA labeling of PNNs in coronal sections of cortex and hippocampus in 12-
1124 month-old mice. Genotypes of the respective mice are indicated. Boxed regions are shown to
1125 the right. Scalebars, 250 μm and 100 μm .
1126 (G) Quantification of colocalization between WFA and Pv labeling per unit area (UA) in
1127 hippocampus and cortex. N=3 mice/group.
1128 (H) CTCF in HPC and CTX. N=3 mice/group, n=230 cells/animal.
1129 (I) Semi-quantitative analysis of high magnification WFA showing increased hole size and
1130 disruption of PNNs in RSP cortex of 12-month mice. N=3 mice/group, n=20 cells/animal.
1131 (J) Fluorescent WFA label of PNNs in RSP cortex of 12-month-old mice. Genotypes of the
1132 respective mice are indicated. Scalebars, 5 μm . Error bars indicate mean \pm SEM. N=3/group.
1133

Supplemental Figure 3



1134

1135 **Supplemental Figure 3.** WFA labeling is reduced across cortical regions.


1136 (A, B) Corrected Total Cell Fluorescence (CTCF) across cortical regions at one- and 12-months of
1137 age. RSP, retrosplenial cortex; MOp, primary motor cortex; MOs, secondary motor cortex; SSp,
1138 primary somatosensory cortex; SSs, secondary somatosensory cortex. Error bars indicate mean
1139 \pm SEM. N=3/group.

1140 (C) Schematic of cortical regions where CTCF was measured.

1141 (D) WFA labeling of PNNs showing grading scale used for analysis in Figures 3d and 3i. Scalebar,
1142 5 μ m.


1143

Figure 4



1145 **Figure 4.** Mice lacking AnkR in GABAergic forebrain interneurons have reduced anxiety.
1146 **(A)** 30 minute-long recordings of mouse trajectories in the open field assay. Genotypes are
1147 indicated.
1148 **(B)** The percent of time spent in the center or perimeter of the open field.
1149 **(C)** The percent of the total path spent in the center or perimeter of the open field.
1150 **(D)** 10 minute long recordings of mouse trajectories in the elevated plus maze.
1151 **(E)** The distance traveled in the open arm, closed arm, or the center of the elevated plus maze.
1152 **(F)** The time spent in the open arm, closed arm, or the center of the elevated plus maze.
1153 **(G)** The number of entries into the open arm, closed arm, or center of the elevated plus maze.
1154 In all panels error bars indicate mean \pm SEM. Black circles indicate the animals corresponding
1155 to the representative traces.
1156

Supplemental Figure 4



1157

1158

Supplemental Figure 4. Quantification of open field and elevated plus maze assays.

1159

(A-C) Measurements of velocity (A), distance traveled (B), and rotations (C) in the open field test.

1160

1161

(D, E) Measurements of velocity (D) and distance (E) in the elevated plus maze assay. In all

1162


panels error bars indicate mean ± SEM. Black circles indicate the animals corresponding to the

1163

representative traces in **Figure 4**.

1164

Figure 5



1165

1166

1167 **Figure 5.** WFA⁺ neurons in *Ank1^{F/F};Dlx5/6-Cre* mice have abnormal action potentials and spike
1168 train characteristics.

1169 **(A)** A representative action potential illustrating the measurement of action potential
1170 parameters. AHP, afterhyperpolarization.

1171 **(B-D)** Summary data showing the action potential latency **(B)**, action potential threshold **(C)**,
1172 and action potential amplitude **(D)** from the single action potential evoked by rheobase current.

1173 **(E)** Representative single action potentials evoked by rheobase currents from *Ank1^{F/F}*,
1174 *Ank1^{+/+};Dlx5/6-Cre*, and *Ank1^{F/F};Dlx5/6-Cre* cells. Action potentials are aligned at 50% of the
1175 rising phase on X axis and peak on Y axis. Note the wider action potential with shallower and
1176 delayed afterhyperpolarization in *Ank1^{F/F};Dlx5/6-Cre* cell.

1177 **(F-H)** Summary data showing the action potential half-width **(F)**, afterhyperpolarization time
1178 **(G)**, and afterhyperpolarization amplitude **(H)** from the single action potentials evoked by
1179 rheobase currents.

1180 **(I)** Representative spike trains from *Ank1^{f/f}*, *Ank1^{+/+};Dlx5/6-Cre*, and *Ank1^{F/F};Dlx5/6-Cre* cells in
1181 response to 500-ms current injection. Left and right traces show the spike trains evoked by
1182 currents that are 2 and 3 times of the action potential threshold currents, respectively. Note
1183 the strong amplitude adaptation and premature depolarization block indicated by the arrow in
1184 the right trace of *Ank1^{F/F};Dlx5/6-Cre* cell.

1185 **(J)** The average firing frequency during 500-ms current injection as a function of injected
1186 currents. Note, recording was stopped at maximal 1450 pA current or when cells reached
1187 depolarization block. Since 13 out of 15 *Ank1^{f/f};Dlx5/6-Cre⁺* cells reached depolarization block
1188 prior to 1450 pA current while only 3 out of 19 control cells reached depolarization block prior
1189 to 1450 pA, the firing frequency is overestimated in the high current range for *Ank1^{F/F};Dlx5/6-
1190 Cre* neurons.


1191 **(K-M)** Summary data showing the average firing frequency during the first 100 ms **(K)**, spike
1192 frequency adaptation **(L)**, and amplitude adaptation **(M)** from the spike trains evoked by
1193 currents that are 2 times of the action potential threshold currents.

1194 **(N)** Summary data showing the minimal currents that caused the cells to enter depolarization
1195 block. If the maximal injected current (1450 pA) did not cause depolarization block, then 1450
1196 pA was recorded as the result. For all panels, each circle represents one neuron and the black
1197 circles indicate the representative cells in **(E and I)**. Bar graphs represent mean \pm SEM.

1198 Statistical significance was determined by one-way ANOVA or Kruskal-Wallis test with multiple
1199 comparisons.

1200


Supplemental Figure 5



1201
1202


1203 **Supplemental Figure 5.** Fluorescein-WFA labeling of perineuronal nets in live slices for
1204 electrophysiology.
1205 **(A)** Top: low magnification image of a coronal slice from the left hemisphere of an *Ank1^{ff}*
1206 mouse after recording. Lines on the brain slice are the indentations resulted from the mesh
1207 used to hold the slice in place during recording. Bottom: high magnification image of the
1208 somatosensory cortex layer 5 within the boxed region in the low magnification image where
1209 recording was performed.
1210 **(B, C)** Same as in **(A)** except for *Ank1^{+/+};Dlx5/6-Cre* **(B)** and *Ank1^{F/F};Dlx5/6-Cre* **(C)**.
1211 **(D)** Representative traces of miniature excitatory postsynaptic currents (mEPSCs) recorded at –
1212 70 mV (top) and miniature inhibitory postsynaptic currents (mIPSCs) recorded at +10 mV
1213 (bottom) from *Ank1^{F/F}*, *Ank1^{+/+};Dlx5/6-Cre*, and *Ank1^{F/F};Dlx5/6-Cre* cells.
1214 **(E, F)** Summary data of mEPSC frequency **(E)** and amplitude **(F)**.
1215 **(G, H)** Summary data of mIPSC frequency **(G)** and amplitude **(H)**.
1216 **(I)** Summary data of excitation/inhibition ratio that is the ratio between the integrated mEPSC
1217 charge per unit time and integrated mIPSC charge per unit time.
1218 Each circle represents one neuron and the black circles indicate the representative cells in **(D)**.
1219 Error bars indicate mean ± SEM. Statistical significance was determined by one-way ANOVA or
1220 Kruskal-Wallis test with multiple comparisons.
1221

Figure 6



1223 **Figure 6.** AnkR binds to Kv3.1b K⁺ channels and is both necessary and sufficient for its
1224 membrane localization and clustering.
1225 **(A, B)** Immunostaining of 1-month-old somatosensory cortex for AnkR (red) and Kv3.1b (green).
1226 Low magnification images are shown in **(A)** and high magnification images in **(B)**. The
1227 genotypes analyzed are shown. Scalebars, 50 μ m in **(A)** and 10 μ m in **(B)**.
1228 **(C)** Immunostaining of human cortical biopsies from two separate patients using antibodies
1229 against AnkR (red) and Kv3.1b (green), and DAPI (blue) to label nuclei (Nu). Scalebars, 10 μ m.
1230 **(D)** Quantification of Kv3.1b immunofluorescence intensity in control and *Ank1^{F/F};Dlx5/6-Cre*
1231 mice.
1232 **(E)** Immunoblots of brain homogenates from 3 one-month-old control and 3 one-month-old
1233 AnkR-deficient brains using antibodies against Kv3.1b, AnkR, and NFM.
1234 **(F)** Quantification of Kv3.1b protein normalized to NFM.
1235 **(G, H)**. Immunoblots of AnkR-GFP immunoprecipitations in cells co-expressing AnkR-GFP with
1236 Myc-tagged β 1 spectrin, full length Flag-tagged Kv3.1b, or truncated versions of Flag-tagged
1237 Kv3.1b. The amino acids included in the Flag-tagged Kv3.1b truncation mutants are indicated.
1238 **(I)** The consensus AnkR-binding motif present in Kv3.1b and Kv3.3, but not Kv3.2.
1239 **(J)** Immunoblots of Kv3.1b, AnkR, and Kv2.1 immunoprecipitation reactions using antibodies
1240 against AnkR and Kv3.1b.
1241 **(K)** Immunostaining of ventral root nodes of Ranvier in *Ank3^{F/+}* and *Ank3^{F/F};ChAT-Cre* mice using
1242 antibodies against AnkG (green), Kv7.2 (red), and neurofascin (NFasc, blue) on the left, and
1243 AnkR (green), Kv3.1b (red), and NFasc (blue) on the right. Scalebars, 1 μ m.
1244 **(L)** Quantification of the percentage of nodes of Ranvier labeled for Kv7.2, Kv3.1b, AnkG, and
1245 AnkR in *Ank3^{F/+}* and *Ank3^{F/F};ChAT-Cre* mice. 60-116 nodes/group. Error bars indicate mean \pm
1246 SEM.

Supplemental Figure 6



1247

1248 **Supplemental Figure 6.** Kv3.1b membrane localization requires AnkR.

1249 (A) Immunolabeling of 12-month-old somatosensory cortex from *Ankr1^{F/F}* and *Ankr1^{F/F};Dlx5/6-*

1250 *Cre* mice using antibodies against AnkR (red) and Kv3.1b (green). Scalebar, 50 μ m.

1251 (B) Immunoblots of brain homogenates from three 12-month-old control and three 12-month-

1252 old AnkR-deficient brains using antibodies against Kv3.1b, AnkR, and NFM.

1253 (C) Quantification of Kv3.1b protein normalized to NFM.

1254 (D) Immunolabeling of 1-month-old somatosensory cortex from *Ankr1^{F/F}* mice using antibodies

1255 against AnkR (red) and Kv3.3 (green). Scalebar, 25 μ m.

1256 (E) Immunostaining of *Ankr1^{F/F}* spinal cord using antibodies against AnkR (red) and Kv3.1b

1257 (green). Scalebars, 10 μ m and 1 μ m.


1258 (F) Immunostaining of ventral root nodes of Ranvier in *Ankr3^{+/+}* and *Ankr3^{F/F};ChAT-Cre* mice using

1259 antibodies against AnkR (red), Kv3.3 (green), and NFasc (blue). Scalebar, 1 μ m.

1260 (G) The specific K⁺ channels and spectrins found at nodes of Ranvier is dictated by the Ankyrin

1261 scaffold to which they bind.

Figure 7



1262 **Figure 7.** AnkR is highly expressed in the somatodendritic domain of Pv^+ interneurons which
 1263 are surrounded by PNNs, a specialized ECM structure.
 1264 AnkR is a scaffolding protein that binds to and stabilizes PNN-associated CAMs (including
 1265 NrCAM and PlexinA4) and ion channels (including Kv3.1b) by linking them to the β 1- α 2
 1266 spectrin-based cytoskeleton. Loss of AnkR results in **1)** altered PNN morphology including
 1267 reduced WFA intensity and decreased compactness of the nets; **2)** molecular changes including
 1268 reduced β 1 spectrin, PNN-associated NrCAM, and Kv3.1b; **3)** behavioral changes including
 1269 decreased anxiety-like behaviors in the open field and elevated plus maze; and **4)**
 1270 electrophysiological changes including decreased AP latency and threshold, broader APs with
 1271 shallower and delayed AHP, and decreased firing rate during current injection.
 1272

Supplemental Table 1.

				p value (One-Way ANOVA or Kruskal-Wallis test)		
	<i>Ank1^{F/F}</i>	<i>Ank1^{+/+}; Dlx5/6-Cre</i>	<i>Ank1^{F/F}; Dlx5/6-Cre</i>	<i>Ank1^{F/F}</i> vs. <i>Ank1^{+/+};</i> <i>Dlx5/6-Cre</i>	<i>Ank1^{F/F}</i> vs. <i>Ank1^{F/F};</i> <i>Dlx5/6-Cre</i>	<i>Ank1^{+/+};</i> <i>Dlx5/6-Cre</i> vs. <i>Ank1^{F/F};</i> <i>Dlx5/6-Cre</i>
Resting membrane potential (mV)	-66.69 ± 1.373 (19)	-70.42 ± 0.934 (17)	-68.8 ± 1.102 (30)	0.1176	0.403	0.6037
Input resistance (MΩ)	109 ± 10.56 (19)	131.7 ± 15.94 (17)	129.6 ± 7.544 (30)	0.6384	0.1419	>0.9999
Membrane capacitance (pF)	82.27 ± 4.849 (19)	81.85 ± 25.74 (17)	67.17 ± 4.068 (30)	0.9983	0.0708	0.0956
Rheobase current (pA)	307.1 ± 24.56 (19)	315.9 ± 26.85 (17)	300.5 ± 17.75 (30)	0.9652	0.9743	0.8768
Action potential latency (ms)	128 ± 39.41 (19)	152.2 ± 44.77 (17)	43.71 ± 18.01 (30)	>0.9999	0.0973	0.0246
Action potential threshold (mV)	-33.51 ± 1.107 (19)	-33.09 ± 1.416 (17)	-37.62 ± 1.087 (30)	0.9766	0.0165	0.0116
Action potential amplitude (mV)	50.88 ± 2.419 (19)	53.12 ± 2.858 (17)	50.41 ± 1.965 (30)	0.8152	0.9881	0.6962
Action potential half-width (ms)	0.3765 ± 0.015 (19)	0.3486 ± 0.014 (17)	0.5316 ± 0.001 (30)	0.3124	<0.0001	<0.0001
Afterhyperpolarization amplitude (mV)	26.07 ± 0.773 (19)	26.9 ± 0.923 (17)	19.19 ± 0.747 (30)	>0.9999	<0.0001	<0.0001
Afterhyperpolarization time (ms)	1.442 ± 0.119 (19)	1.318 ± 0.087 (17)	1.913 ± 0.088 (30)	0.9943	0.0002	<0.0001
Spike frequency adaptation	0.897 ± 0.025 (13)	0.9326 ± 0.017 (13)	0.8912 ± 0.022 (24)	0.9982	>0.9999	0.721
Spike amplitude adaptation	0.8243 ± 0.012 (13)	0.8446 ± 0.075 (13)	0.6731 ± 0.027 (24)	>0.9999	0.0013	0.0001
Firing frequency (Hz)	221.5 ± 9.257 (13)	329.2 ± 11.06 (13)	204.6 ± 5.516 (24)	0.5423	0.6966	0.0196
Depolarization block current (pA)	1438 ± 12.50 (8)	1335 ± 59.48 (13)	1006 ± 77.44 (16)	>0.9999	0.0031	0.0048


1273

1274 **Supplemental Table 1.** Intrinsic properties of WFA⁺ cells in *Ank1^{F/F}*, *Ank1^{+/+};Dlx5/6-Cre*, and
 1275 *Ank1^{F/F};Dlx5/6-Cre* mice. Data are from 3 *Ank1^{F/F}*, 2 *Ank1^{+/+};Dlx5/6-Cre*, and 4 *Ank1^{F/F};Dlx5/6-Cre*
 1276 mice, and are reported as mean ± SEM (number of cells). Bolded p values indicate significance.

1277


1278

1279 **Supplemental Movie 1.** WFA in 12-month *Ank1^{F/F}*. Scalebar, 5 μ m.



1280

1281 **Supplemental Movie 2.** WFA in 12-month *Ank1^{F/F};Dlx5/6-Cre*. Scalebar, 5 μ m.



1282

1283